

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
3 April 2003 (03.04.2003)

PCT

(10) International Publication Number
WO 03/026667 A1

(51) International Patent Classification⁷: A61K 31/517,
31/47, A61P 13/10, C07D 239/72, 215/38

Honeysuckle Road, Lake Forest, IL 60045 (US). WAN,
Honghe; 720 Forest Street, Kearny, NJ 07032 (US).

(21) International Application Number: PCT/US02/30259

(74) Agent: WHITE, John, P.; Cooper & Dunahm LLP, 1185
Avenue of the Americas, New York, NY 10036 (US).

(22) International Filing Date:

24 September 2002 (24.09.2002)

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC,
VN, YU, ZA, ZM, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

09/963,129 24 September 2001 (24.09.2001) US

(71) Applicant: SYNAPTIC PHARMACEUTICAL COR-
PORATION [US/US]; 215 College Road, Paramus, NJ
07652 (US).

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK,
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).


(72) Inventors: KAWAKAMI, Joel, K.; 49 Blakely Lane,
Newfoundland, NJ 07435 (US). KONKEL, Michael,
J.; 69 MacArthur Avenue, Garfield, NJ 07026 (US).
BOTEJU, Lakmal, W.; 39 Grissing Court, Cedar Grove,
NJ 07009 (US). WETZEL, John, M.; 16-08 Well Drive,
Fairlawn, NJ 07410 (US). NOBLE, Stewart, A.; 75 West

Published:


— with international search report

[Continued on next page]

(54) Title: QUINAZOLINO- AND QUINOLINO- GUANIDINES AS LIGANDS FOR THE NEUROPEPTIDE FF (NPFF) RE-
CEPTORS



Bladder
Pressure
(mmHg)



Saline compound 4005 (1 mg/kg, i.v.)

(57) Abstract: This invention provides compounds having the structure formula (I); wherein X= CH, C(CH₃) or N; each of R₁, R₂, R₃, R₄ and R₅ is independently H, C₁-C₁₀ straight chained or branched alkyl, C₂-C₁₀ straight chained or branched alkenyl, C₂-C₁₀ straight chained or branched alkynyl, C₃-C₁₀ cycloalkyl, substituted or unsubstituted aryl, hydroxy, halogenated ether, nitro, amino, halogen, -CN, -C(=Z)R₆, -C(=Z)OR₆, -C(=Z)N(R₆)₂, -N(R₆)-C(=Z)R₆, -N(R₆)-C(=Z)N(R₆)₂, -OC(=Z)R₆, -C(=Z)OR₆ or SR₆; wherein Z is O or S; and wherein R₆ is C₁-C₁₀ straight chained or branched alkyl, aryl, (CH₂)_nQ, C₂-C₁₀ alkenyl, C₃-C₁₀ cycloalkyl, C₃-C₁₀ cycloalkenyl, c₃-c₁₀ cycloalkenyl, wherein Q is OR₇, SR₇, N(R₇)₂ or aryl, wherein R₇ is H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, wherein R₂ and R₃ and the carbons to which they are attached form a fused aryl, heteroaryl, C₃-C₁₀ cyclic alkyl or heterocyclic alkyl ring; or wherein R₃ and R₄ and the carbons to which they are attached form a fused aryl, heteroaryl, cyclic alkyl or heterocyclic alkyl ring; and wherein each alkyl, alkenyl, alkynyl and alkoxy group is optionally substituted with a substituent independently selected from R_a, where R_a is 1) hydroxy, 2) C₁-C₁₀ alkoxy, 3) halogen, 4) nitro, 5) amino, 6) CF₃, or 7) carboxy, and each cycloalkyl group is optionally substituted with a substituent independently selected from R_b, where R_b is 1) a group selected from R_a, 2) C₁-C₇ alkyl, 3) C₂-C₇ alkenyl, 4) C₂-C₇ alkynyl or 5) cyclic C₁-C₁₀ alkyl, and each aryl is optionally substituted with R₁. This invention also provides methods of treating pain, urge incontinence; as well as methods of preparing the compounds.



For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

QUINAZOLINO- AND QUINOLINO- GUANIDINES AS LIGANDS FOR THE
NEUROPEPTIDE FF (NPFF) RECEPTORS

This application claims priority of U.S. Serial No. 09/963,129, filed September 24, 2001, the contents of which are hereby incorporated by reference into the application.

Throughout this application, various publications are referenced within parentheses. Disclosures of these publications in their entireties are hereby incorporated by reference into this application to more fully describe the state of the art to which this invention pertains. Full bibliographic citations for these references may be found immediately preceding the claims.

10 BACKGROUND OF THE INVENTION

NPFF is an octapeptide isolated from bovine brain in 1985 by Yang and coworkers (1) using antibodies to the molluscan neuropeptide FMRFamide (FMRFa). FMRFamide-like immunoreactivity was observed in rat brain, spinal cord, and pituitary, suggesting the existence of mammalian homologs of the FMRFa family of invertebrate peptides. The isolation of NPFF, named for its N- and C-terminal phenylalanines (also called F8Famide) and a second mammalian peptide, NPAF (also called A18Famide), confirmed the existence of a mammalian family of peptides sharing C-terminal sequence homology with FMRFa (1). Molecular cloning has revealed that NPFF and NPAF are encoded by the same gene and cleaved from a common precursor protein (2). Studies of the localization,

radioligand binding, and function of NPFF-like peptides indicate they are neuromodulatory peptides whose effects are likely to be mediated by G protein-coupled receptors (4).

5 There are two known receptor subtypes for NPFF, NPFF-1 and NPFF-2 (3). Recently, two NPFF receptor subtypes (NPFF-1 and NPFF-2) were discovered and cloned from rat and human tissues (4). The localization of protein and mRNA for these two
10 receptors indicates that they may have utility as targets for drugs to treat a variety of disorders including, but not limited to, disorders of electrolyte balance, diabetes, respiratory disorders, gastrointestinal disorders, depression, phobias, anxiety, mood disorders, cognition/memory disorders, obesity, pain, alertness/sedation, lower urinary tract
15 disorders and cardiovascular indications.

NPFF is an endogenous modulator of opioid systems with effects on morphine analgesia, tolerance, and withdrawal (5, 6). NPFF appears to represent an endogenous "anti-opioid" system in the
20 CNS, acting at specific high-affinity receptors that are distinct from opioid receptors (7, 8). Endogenous NPFF has been suggested to play a role in morphine tolerance: agonists of NPFF precipitate "morphine abstinence syndrome" (symptoms of morphine withdrawal) in morphine-dependent animals (9, 10),
25 while antagonists and anti-NPFF IgG restore morphine sensitivity and ameliorate symptoms of withdrawal. NPFF has also been shown to participate in the regulation of pain threshold, showing both "anti-opiate" effects and analgesic effects, depending on the test system (5).

The ability of NPFF peptides to modulate the opioid system raised the possibility that NPFF interacts directly with opiate receptors. However, radioligand binding assays using a tyrosine-substituted NPFF analog [¹²⁵I]Y8Fa demonstrate that
5 NPFF acts through specific high affinity binding sites distinct from opiate receptors (11-14) that are sensitive to inhibition by guanine nucleotides (15).

NPFF and related peptidic agonists exhibit direct analgesic
10 activity in some animal models. NPFF has been shown to produce analgesia in the rat tail-flick and paw pressure models, upon intrathecal administration (16). Similarly, a NPFF-like peptide, SLAAPQRF-amide, isolated from rat brain and spinal cord (17), produces antinociceptive action in the tail-flick
15 and paw pressure models (18). NPFF has also been observed to play a role in animal models of chronic pain. For example, NPFF has recently been shown to be involved in inflammatory pain (19) and neuropathic pain (20). Importantly, NPFF was shown to attenuate the allodynia associated with neuropathic
20 pain, suggesting that it may be clinically useful in treating this condition. NPFF also has been shown to produce nighttime hyperalgesia in the tail-flick test upon i.c.v. administration in the rat (21). A peptidic NPFF analog, (D)Tyr¹, (NMe)Phe³- NPFF (1DMe, 1DMeY8Fa), which is
25 partially protected against enzymatic degradation and also has high affinity for its receptors, shows long-lasting analgesic activity in the above models upon intrathecal administration (22, 23). In carrageenan inflammation, 5-10nmol of 1DMe was effective against both thermal hyperalgesia and mechanical

allodynia, and in a neuropathic pain model, 1DMe showed antiallodynic effects against cold allodynia (24). 1DMe also shows analgesic activity in the rat vocalization threshold upon intrathecal administration (25).

5

Recent studies in our laboratories have shown that NPFF also has peripheral effects. NPFF and related agonists show decrease in the contraction frequency of the rat bladder upon i.v. and i.t. administration (See PCT International Publication No. WO 00/18438). A potent NPFF agonist, PFRF-amide, has been shown to increase blood pressure and heart rate in rats (26). In addition, NPFF and related peptides have a number of other biological activities that may be therapeutically relevant including effects on feeding (27-29),
10 psychotic behavior (30), nicotine addiction (31), and other
15 cardiovascular functions (32, 33).

Effects on feeding behavior are further supported by findings that demonstrate NPFF-like immunoreactive neurons, as well as
20 NPFF1 receptor mRNA, localize to the hypothalamus (3,5). The NPFF1-selective ligand, BIBP 3226, which is also a neuropeptide Y Y1 antagonist, blocks feeding through a nonspecific mechanism, not secondary to inhibition of Y1 (39). These data suggest that feeding behavior may be regulated
25 through a NPFF1 receptor mechanism.


It is thus evident that NPFF agonists and/or antagonists have great potential as being therapeutically useful agents for the treatment of a diverse array of clinically relevant human

disorders. NPFF agonists may have therapeutic potential, among others, for the treatment of pain, memory loss, circadian rhythm disorders, and micturition disorders. Cloned receptor subtypes of NPFF and the development of high-efficiency in vitro assays, both for binding and receptor activation, has aided the discovery and development of novel NPFF ligands. Moreover, it is practically possible to design a molecule that is an agonist at one NPFF subtype, and an antagonist at the other(s). This concept of a dual-acting molecule provides an attractive means of designing drugs that can treat multiple disorders.

There are no known nonpeptide agonists or antagonists of NPFF in the prior art. Described herein are quinazolino- and quinolino-guanidine containing compounds that may be used to treat an abnormality in a subject wherein the abnormality is alleviated by increasing or decreasing the activity of a mammalian NPFF receptor which comprises administering to the subject an amount of a compound which is an antagonist or agonist of mammalian NPFF receptors to effect a treatment of the abnormality. The compounds of invention herein are the first known small molecule (non-peptide/non-peptoid) ligands (either antagonists or agonists) at the neuropeptide FF (NPFF) receptor(s).

SUMMARY OF THE INVENTION

This invention provides a method of treating urge incontinence in a subject in need of such treatment comprising
 5 administering to the subject an effective amount of a compound having the structure:



wherein X = CH, C(CH₃) or N;

15 wherein each of R₁, R₂, R₃, R₄ and R₅ is independently H, C₁-C₁₀ straight chained or branched alkyl, C₂-C₁₀ straight chained or branched alkenyl, C₂-C₁₀ straight chained or branched alkynyl, C₃-C₁₀ cycloalkyl, substituted or unsubstituted aryl, hydroxy, halogenated ether, nitro, amino, halogen, -CN, -C(=Z)R₆, -
 20 C(=Z)OR₆, -C(=Z)N(R₆)₂, -N(R₆)-C(=Z)R₆, -N(R₆)-C(=Z)N(R₆)₂, -OC(=Z)R₆, -C(=Z)OR₆ -OR₆ or -SR₆;

wherein Z is O or S; and

wherein R₆ is C₁-C₁₀ straight chained or branched alkyl, aryl, (CH₂)_nQ, C₂-C₁₀ alkenyl, C₃-C₁₀ cycloalkyl, C₅-C₁₀
 25 cycloalkenyl,

wherein Q is OR₇, SR₇, N(R₇)₂ or aryl,

wherein R₇ is H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl,

wherein R_2 and R_3 and the carbons to which they are attached form a fused aryl, heteroaryl, C_5 - C_{10} cyclic alkyl or heterocyclic alkyl ring; or wherein R_3 and R_4 and the carbons to which they are attached form a fused aryl, heteroaryl, cyclic alkyl or heterocyclic alkyl ring;

and wherein each alkyl, alkenyl, alkynyl and alkoxy group is optionally substituted with a substituent independently selected from R_a , where R_a is

- 1) hydroxy,
- 2) C_1 - C_{10} alkoxy,
- 3) halogen,
- 4) nitro,
- 5) amino,
- 6) CF_3 , or
- 7) carboxy,

and each cycloalkyl group is optionally substituted with a substituent independently selected from R_b , where R_b is

- 1) a group selected from R_a ,
- 2) C_1 - C_7 alkyl,
- 3) C_2 - C_7 alkenyl,
- 4) C_2 - C_7 alkynyl or
- 5) cyclic C_1 - C_{10} alkyl,

and each aryl is optionally substituted with R_1 ,
to thus treat the urge incontinence in the subject.

8

This invention also provides a method of treating pain in a subject in need of such treatment comprising administering to the subject an effective amount of the aforementioned compound.

5

10

15

20

25

BRIEF DESCRIPTION OF THE FIGURES


Figure 1: Shows the correlation between the binding affinities at human and rat recombinant neuropeptide FF receptors. The binding affinities (pKi values) for 18 compounds were tested at rat NPFF receptors and plotted against the pKi values for the same 18 compounds tested at human NPFF2 receptors. A slope value of 0.83 was obtained for rat NPFF1 vs. human NPFF1 and a slope value of 0.75 was obtained for rat NPFF2 vs. human NPFF2, both slope values of which indicate a positive correlation.

Figure 2: Shows the effect of compound (4006) on bladder activity in the anesthetized rat. Rhythmic elevations in bladder pressure, resulting from distension induced contractions, were unaffected by the i.v. administration of physiological saline. In contrast, the NPFF receptor ligand compound (4006) produced an immediate inhibition of bladder activity, which persisted for 12 min.

Figure 3: Shows the effect of compound (4005) on bladder activity in the anesthetized rat. Rhythmic elevations in bladder pressure, resulting from distension induced contractions, were unaffected by the i.v. administration of physiological saline. In contrast, the NPFF receptor ligand compound (4005) produced an immediate inhibition of bladder activity, which persisted for 35 min.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides a method of treating urge incontinence in a subject in need of such treatment comprising administering to the subject an effective amount of a compound having the structure:



wherein X = CH, C(CH₃) or N;

15 wherein each of R₁, R₂, R₃, R₄ and R₅ is independently H, C₁-C₁₀ straight chained or branched alkyl, C₂-C₁₀ straight chained or branched alkenyl, C₂-C₁₀ straight chained or branched alkynyl, C₃-C₁₀ cycloalkyl, substituted or unsubstituted aryl, hydroxy, halogenated ether, nitro, amino, halogen, -CN, -C(=Z)R₆, -C(=Z)OR₆, -C(=Z)N(R₆)₂, -N(R₆)-C(=Z)R₆, -N(R₆)-C(=Z)N(R₆)₂, -OC(=Z)R₆, -C(=Z)OR₆ -OR₆ or -SR₆;

wherein Z is O or S; and

wherein R₆ is C₁-C₁₀ straight chained or branched alkyl, aryl, (CH₂)_nQ, C₂-C₁₀ alkenyl, C₃-C₁₀ cycloalkyl, C₅-C₁₀ cycloalkenyl,

25 wherein Q is OR₇, SR₇, N(R₇)₂ or aryl,

wherein R₇ is H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl,

wherein R_2 and R_3 and the carbons to which they are attached form a fused aryl, heteroaryl, C_5 - C_{10} cyclic alkyl or heterocyclic alkyl ring; or wherein R_3 and R_4 and the carbons to which they are attached form a fused aryl, heteroaryl, cyclic alkyl or heterocyclic alkyl ring;

and wherein each alkyl, alkenyl, alkynyl and alkoxy group is optionally substituted with a substituent independently selected from R_a , where R_a is

- 1) hydroxy,
- 2) C_1 - C_{10} alkoxy,
- 3) halogen,
- 4) nitro,
- 5) amino,
- 6) CF_3 , or
- 7) carboxy,

and each cycloalkyl group is optionally substituted with a substituent independently selected from R_b , where R_b is

- 1) a group selected from R_a ,
- 2) C_1 - C_7 alkyl,
- 3) C_2 - C_7 alkenyl,
- 4) C_2 - C_7 alkynyl or
- 5) cyclic C_1 - C_{10} alkyl,

and each aryl is optionally substituted with R_1 ,
to thus treat the urge incontinence in the subject.

This invention also provides a method of treating pain in a subject in need of such treatment comprising administering to the subject an effective amount of any of the aforementioned compounds.

5

In one embodiment of the aforementioned method, wherein R_1 may be methyl or ethyl;

wherein R_2 is H or fused benzene;

10

wherein R_3 is H, methyl, ethyl, propyl, tert-butyl, octyl, cyclohexyl, phenyl, hydroxy, methoxy, butoxy, pentoxy, phenoxy, benzoxy, trifluoromethyl ether, methylbenzene ether, 5-phenoxypropyloxy, 4-Hydroxypentyl, Cl, Br, F, or wherein R_2 and R_3 and the carbons to which they are attached form a fused benzene, fused 5,6-cyclohexenyl, fused cyclopentyl, or fused 2,3-furyl; and

15

wherein R_4 is H, methyl, ethyl, isopropyl, tert-butyl, 1-hydroxyethyl, ethoxy, butoxy, isopropoxy, phenoxy, benzyloxy, trifluoromethyl ether, Br, F, or wherein R_3 and R_4 and the carbons to which they are attached form a fused benzene, fused 5,6-cyclohexenyl, fused cyclopentyl, or fused 2,3-furyl.

20

In another embodiment of the aforementioned method, wherein R_1 is methyl or ethyl;

25

wherein R_2 is H;

wherein R_3 is propyl, octyl, cyclohexyl, phenyl, hydroxy, methoxy, butoxy, pentoxy, phenoxy, benzoxy, trifluoromethyl ether, methylbenzene ether, 4-Hydroxypentyl, Cl, Br, F, or
5 wherein R_2 and R_3 and the carbons to which they are attached form fused 5,6-cyclohexenyl, fused cyclopentyl, or fused 2,3-furyl; and

wherein R_4 is H, methyl, ethyl, isopropyl, tert-butyl, 1-hydroxy ethyl, ethoxy, butoxy, isopropoxy, phenyl, Br, F, or
10 wherein R_3 and R_4 and the carbons to which they are attached form a fused 5,6-cyclohexenyl, fused cyclopentyl, or fused 2,3-furyl.

In another embodiment of the aforementioned method, wherein R_1
15 is methyl or ethyl;

wherein R_2 is H;

wherein R_3 is cyclohexyl, benzoxy, pentoxy, phenoxy, trifluoromethyl ether, methylbenzene ether, 4-hydroxypentyl,
20 or wherein R_2 and R_3 and the carbons to which they are attached form fused 5,6-cyclohexenyl, fused cyclopentyl, or fused 2,3-furyl; and

25 wherein R_4 is H, 1-hydroxyethyl, trifluoromethyl ether, or wherein R_3 and R_4 and the carbons to which they are attached form fused 5,6-cyclohexenyl, fused cyclopentyl or fused 2,3-furyl.

14

In another embodiment of the aforementioned method, wherein R_1 is methyl or ethyl;

wherein R_2 is H;

5

wherein R_3 is cyclohexyl, pentoxy, phenoxy, trifluoromethyl ether, methylbenzene ether, 4-hydroxypentyl, or wherein R_2 and R_3 and the carbons to which they are attached form fused 5,6-cyclohexenyl, fused cyclopentyl, or fused 2,3-furyl;


10

wherein R_4 is H, 1-hydroxyethyl, trifluoromethyl ether, or wherein R_3 and R_4 and the carbons to which they are attached form fused 5,6-cyclohexenyl, fused cyclopentyl, or fused 2,3-furyl.

15

In another embodiment of the aforementioned method, a compound having the structure:

20



25


wherein R_3 is H, straight chained or branched C_1 - C_7 alkyl or aryl.

In another embodiment of the aforementioned method, wherein R_3 is butyl, sec-butyl, pentyl, hexyl, heptyl, or benzyl.

15

In another embodiment of the aforementioned method, wherein R_3 is butyl, sec-butyl, hexyl, heptyl, or benzyl.

In another embodiment of the aforementioned method, the
5 compound has the structure:




10

wherein R_4 is H, straight chained or branched C₁-C₇ alkyl.

In another embodiment of the aforementioned method, wherein R_4
15 is H, or methyl.

In another embodiment of the aforementioned method, the
compound has the structure:



20

25 wherein R_2 is H or methyl;

wherein R_3 is H, straight chained or branched C₁-C₇ alkyl, aryl, alkoxy or halogen, or wherein R_2 and R_3 and the carbons to which they are attached form a fused aryl; and

16

wherein R_4 is H, methyl or halogen.

In another embodiment of the aforementioned method, wherein R_2 is H, methyl;


5

wherein R_3 is H, Cl, methyl, ethyl, methoxy, phenyl or wherein R_2 and R_3 and the carbons to which they are attached form fused benzene; and

10 wherein R_4 is H, methyl or F.

In another embodiment of the aforementioned method, the compound has the structure:

15



20 wherein R_3 is H, straight chained or branched C_1 - C_7 alkyl.


In another embodiment of the aforementioned method, wherein R_3 is butyl, pentyl or hexyl.

25

17

In another embodiment of the aforementioned method, the compound has the structure:

5



10

wherein R_1 is H, straight chained or branched C_1 - C_7 alkyl; and
wherein each R_4 and R_5 is independently H or straight chained or branched C_1 - C_7 alkyl.

15


In another embodiment of the aforementioned method, wherein R_1 is methyl or ethyl; and

wherein each R_4 and R_5 is independently H or methyl.

20

In another embodiment of the aforementioned method, the compound has the structure:

25




(1001)

18

In another embodiment of the aforementioned method, the compound has the structure:


5



(1002)

10 In another embodiment of the aforementioned method, the compound has the structure:


15



(1003)

20 In another embodiment of the aforementioned method, the compound has the structure:


25



(1004)


19

In another embodiment of the aforementioned method, the compound has the structure:



(1005)


10 In another embodiment of the aforementioned method, the compound has the structure:



15

(1006)

20 In another embodiment of the aforementioned method, the compound has the structure:




25

(1007)

20


In another embodiment of the aforementioned method, the compound has the structure:

5




(1008)

10 In another embodiment of the aforementioned method, the compound has the structure:



(1009)


20 In another embodiment of the aforementioned method, the compound has the structure:



(1010)


21

In another embodiment of the aforementioned method, the compound has the structure:



(1011)


10 In another embodiment of the aforementioned method, the compound has the structure:



15

(1012)

20 In another embodiment of the aforementioned method, the compound has the structure:




25

(1013)

22

In another embodiment of the aforementioned method, the compound has the structure:

5




(1026)

10

In another embodiment of the aforementioned method, the compound has the structure:


15



(1015)

20

In another embodiment of the aforementioned method, the compound has the structure:




(1016)

23


In another embodiment of the aforementioned method, the compound has the structure:

5



(1017)


10 In another embodiment of the aforementioned method, the compound has the structure:



(1018)

20 In another embodiment of the aforementioned method, the compound has the structure:

25




(1019)

24

In another embodiment of the aforementioned method, the compound has the structure:


5



(1020)

10 In another embodiment of the aforementioned method, the compound has the structure:


15



(1021)

In another embodiment of the aforementioned method, wherein the compound has the structure:

20




25

(1022)

25

In another embodiment of the aforementioned method, the compound has the structure:


5



(1023)

10 In another embodiment of the aforementioned method, the compound has the structure:


15



(1024)

20 In another embodiment of the aforementioned method, the compound has the structure:

25




(1025)

26

In another embodiment of the aforementioned method, the compound has the structure:


5



(1014)

10 In another embodiment of the aforementioned method, the compound has the structure:


15



(1015)

20 In another embodiment of the aforementioned method, the compound has the structure:

25




(1027)

27

In another embodiment of the aforementioned method, the compound has the structure:


5



(1029)

10 In another embodiment of the aforementioned method, the compound has the structure:


15



(1030)

20 In another embodiment of the aforementioned method, the compound has the structure:

25




(1031)

28

In another embodiment of the aforementioned method, the compound has the structure:


5



(1032)

10 In a further embodiment of the above described method, wherein the compound has the structure:


15



(1033)

20 In another embodiment of the aforementioned method, the compound has the structure:

25




(1034)

29

In another embodiment of the aforementioned method, the compound has the structure:


5



(1035)

10 In another embodiment of the aforementioned method, the compound has the structure:


15



(1036)

20 In another embodiment of the aforementioned method, the compound has the structure:

25




(1037)

30

In another embodiment of the aforementioned method, the compound has the structure:


5



(1038)


10 In another embodiment of the aforementioned method, the compound has the structure:

15



(1039)

20 In another embodiment of the aforementioned method, the compound has the structure:




(2001)

31

In another embodiment of the aforementioned method, the compound has the structure:

5




(2002)

10

In another embodiment of the aforementioned method, the compound has the structure:

15




(2003)

20

In another embodiment of the aforementioned method, the compound has the structure:

25




(2004)

In another embodiment of the aforementioned method, compound has the structure:

32

In a further embodiment of the above described method, wherein the compound has the structure:

5




(2005)

10

In another embodiment of the aforementioned method, the compound has the structure:


15



(2006)

20 In another embodiment of the aforementioned method, the compound has the structure:


25



(3001)

In another embodiment of the aforementioned method, the compound has the structure:


5



(4001)

10 In another embodiment of the aforementioned method, the compound has the structure:


15



(4002)

20 In another embodiment of the aforementioned method, the compound has the structure:

25




(4003)

34

In another embodiment of the aforementioned method, the compound has the structure:


5



(4004)

10 In another embodiment of the aforementioned method, the compound has the structure:


15



(4005)

20 In another embodiment of the aforementioned method, the compound has the structure:

25




(4006)

35

In another embodiment of the aforementioned method, the compound has the structure:


5



(4007)

10 In another embodiment of the aforementioned method, the compound has the structure:


15



(4008)

In another embodiment of the aforementioned method, the compound has the structure:

20




25

(4009)

In another embodiment of the aforementioned method, the compound has the structure:


5



(5001)

10 In another embodiment of the aforementioned method, the compound has the structure:


15



(5002)

20 In another embodiment of the aforementioned method, the compound has the structure:

25




(5003)

37

In another embodiment of the aforementioned method, the compound has the structure:


5



(6001)

10 In another embodiment of the aforementioned method, the compound has the structure:

15




(6002)

20


In another embodiment of the aforementioned method, the compound has the structure:

25



(6003)

This invention further includes a compound having the structure:



wherein each of R_1 , R_2 , R_3 , R_4 and R_5 is independently H, C_1 - C_{10} straight chained or branched alkyl, C_2 - C_{10} straight chained or branched alkenyl, C_2 - C_{10} straight chained or branched alkynyl, C_3 - C_{10} cycloalkyl, substituted or unsubstituted aryl, hydroxy, halogenated ether, nitro, amino, halogen, -CN, -C(=Z) R_6 , -C(=Z)OR $_6$, -C(=Z)N(R_6) $_2$, -N(R_6)-C(=Z) R_6 , -N(R_6)-C(=Z)N(R_6) $_2$, -OC(=Z) R_6 , -C(=Z)OR $_6$ -OR $_6$ or -SR $_6$;

wherein Z is O or S; and

wherein R_6 is C_1 - C_{10} straight chained or branched alkyl, aryl, $(CH_2)_nQ$, C_2 - C_{10} alkenyl, C_3 - C_{10} cycloalkyl, C_5 - C_{10} cycloalkenyl,

20 wherein Q is OR $_7$, SR $_7$, N(R_7) $_2$ or aryl,

wherein R_7 is H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl,

wherein R_2 and R_3 and the carbons to which they are attached form a fused aryl, heteroaryl, C_5 - C_{10} cyclic alkyl or heterocyclic alkyl ring; or wherein R_3 and R_4 and the carbons to which they are attached form a fused aryl, heteroaryl, cyclic alkyl or heterocyclic alkyl ring;

and wherein each alkyl, alkenyl, alkynyl and alkoxy group is optionally substituted with a substituent independently selected from R_a , where R_a is

- 1) hydroxy,
- 5 2) C_1 - C_{10} alkoxy,
- 3) halogen,
- 4) nitro,
- 5) amino,
- 6) CF_3 , or
- 10 7) carboxy,

and each cycloalkyl group is optionally substituted with a substituent independently selected from R_b , where R_b is


- 1) a group selected from R_a ,
- 15 2) C_1 - C_7 alkyl,
- 3) C_2 - C_7 alkenyl,
- 4) C_2 - C_7 alkynyl or
- 5) cyclic C_1 - C_{10} alkyl,

and each aryl is optionally substituted with R_1 .

20

The present invention further includes a compound having the structure:

25



wherein R_2 is H or methyl;

40

wherein R_3 is H, straight chained or branched C_1 - C_7 alkyl, aryl, alkoxy or halogen, or wherein R_2 and R_3 and the carbons to which they are attached form a fused aryl; and

5 wherein R_4 is H, methyl or halogen.

The present invention further includes the aforementioned compound wherein R_2 is H, methyl;


10 wherein R_3 is H, Cl, methyl, ethyl, methoxy, phenyl or wherein R_2 and R_3 and the carbons to which they are attached form fused benzene; and

wherein R_4 is H, methyl or F.

15

The present invention further includes a compound having the structure:

20




wherein R_3 is H, straight chained or branched C_1 - C_7 alkyl.

25 The present invention further includes the aforementioned compound wherein R_3 is propyl, pentyl or hexyl.

41

This invention further includes a compound having the structure:

5



10 wherein R_1 is H, straight chained or branched C_1 - C_7 alkyl; and

wherein each R_4 and R_5 is independently H or straight chained or branched C_1 - C_7 alkyl.

15


This invention further includes the aforementioned compound wherein R_1 is methyl or ethyl; and

wherein each R_4 and R_5 is independently H or methyl.

20

This invention also includes a compound having the structure:

25



wherein each of R_1 , R_2 , R_4 and R_5 is independently H, C_1 - C_{10}

straight chained or branched alkyl, C₂-C₁₀ straight chained or branched alkenyl, C₂-C₁₀ straight chained or branched alkynyl, C₃-C₁₀ cycloalkyl, substituted or unsubstituted aryl, hydroxy, halogenated ether, nitro, amino, halogen, -CN, -
 5 C(=Z)R₆, -C(=Z)OR₆, -C(=Z)N(R₆)₂, -N(R₆)-C(=Z)R₆, -N(R₆)-C(=Z)N(R₆)₂, -OC(=Z)R₆, -C(=Z)OR₆ -OR₆ or -SR₆;

wherein Z is O or S; and

wherein R₆ is C₁-C₁₀ straight chained or branched alkyl, aryl, (CH₂)_nQ, C₂-C₁₀ alkenyl, C₃-C₁₀ cycloalkyl, C₅-C₁₀
 10 cycloalkenyl,

wherein Q is OR₇, SR₇, N(R₇)₂ or aryl,

wherein R₇ is H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl,

15 wherein R₃ is straight chained C₃, C₄, C₆ or C₇ alkyl or branched C₅-C₇ alkyl, C₂-C₁₀ straight chained or branched alkenyl, C₂-C₁₀ straight chained or branched alkynyl, C₃-C₁₀ cycloalkyl, substituted or unsubstituted aryl, hydroxy, halogenated ether, nitro, amino, halogen, -CN, -C(=Z)R₆, -
 20 C(=Z)OR₆, -C(=Z)N(R₆)₂, -N(R₆)-C(=Z)R₆, -N(R₆)-C(=Z)N(R₆)₂, -OC(=Z)R₆, -C(=Z)OR₆ -OR₆ or -SR₆;

wherein Z is O or S; and

wherein R₆ is C₁-C₁₀ straight chained or branched alkyl, aryl, (CH₂)_nQ, C₂-C₁₀ alkenyl, C₃-C₁₀ cycloalkyl, C₅-C₁₀
 25 cycloalkenyl,

wherein Q is OR₇, SR₇, N(R₇)₂ or aryl,

wherein R₇ is H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl,

wherein R_2 and R_3 and the carbons to which they are attached form a fused cyclic alkyl or heterocyclic alkyl ring; or wherein R_3 and R_4 and the carbons to which they are attached form a fused aryl, heteroaryl, cyclic alkyl or heterocyclic alkyl ring; and

and wherein each alkyl, alkenyl, alkynyl and alkoxy group is optionally substituted with a substituent independently selected from R_a , where R_a is


- 1) hydroxy,
- 2) C_1 - C_{10} alkoxy,
- 3) halogen,
- 4) nitro,
- 5) amino,
- 6) CF_3 , or
- 7) carboxy,

and each cycloalkyl group is optionally substituted with a substituent independently selected from R_b , where R_b is

- 1) a group selected from R_a ,
 - 2) C_1 - C_7 alkyl,
 - 3) C_2 - C_7 alkenyl,
 - 4) C_2 - C_7 alkynyl or
 - 5) cyclic C_1 - C_{10} alkyl,
- and each aryl is optionally substituted with R_1 .

This invention also includes the compound having the structure:

44



5

herein R₁ is H, straight chained or branched C₁-C₇ alkyl;

wherein R₂ is H, straight chained or branched C₁-C₇ alkyl or fused aryl;

10

wherein R₃ is straight chained C₃, C₄, C₆ or C₇ alkyl or branched C₅-C₇ alkyl, cycloalkyl, substituted or unsubstituted aryl, hydroxyl, straight chained or branched alkoxy, halogenated ether, or halogen;

15

wherein R₄ is H, branched C₁-C₇ alkyl, aryl, straight chained or branched alkoxy or halogen; or wherein R₂ and R₃ and the carbons to which they are attached form a fused C₃-C₆ cyclic alkyl or heterocyclic alkyl ring; or wherein R₃ and R₄ and the carbons to which they are attached form a fused C₆-C₇ aryl or heteroaryl ring, a fused C₃-C₆ cyclic alkyl or heterocyclic alkyl ring.

20

This invention further includes the aforementioned compound wherein R₁ is methyl or ethyl;

25

wherein R₂ is H or fused benzene;

wherein R₃ is cyclohexyl, phenyl, hydroxy, methoxy, butoxy,

pentoxo, phenoxy, benzoxy, trifluoromethyl ether, methylbenzene ether, 4-Hydroxypentyl, Cl, Br, F, or wherein R₂ and R₃ and the carbons to which they are attached form fused 5,6-cyclohexenyl, fused cyclopentyl, or fused 2,3-furyl; and

5

wherein R₄ is H, isopropyl, tert-butyl, 1-hydroxyethyl, ethoxy, butoxy, isopropoxy, phenyl, Br, F, or wherein R₃ and R₄ and the carbons to which they are attached form fused 5,6-cyclohexenyl, fused cyclopentyl, or fused 2,3-furyl.

10

This invention further includes the aforementioned compound wherein R₁ is methyl or ethyl;

15

wherein R₂ is H or fused benzene;

wherein R₃ is cyclohexyl, benzoxy, pentoxo, phenoxy, trifluoromethyl ether, methylbenzene ether, 4-hydroxypentyl, or wherein R₂ and R₃ and the carbons to which they are attached form fused 5,6-cyclohexenyl, fused cyclopentyl, or fused 2,3-furyl; and

20

wherein R₄ is H, 1-hydroxyethyl, trifluoromethyl ether, or wherein R₃ and R₄ and the carbons to which they are attached form fused 5,6-cyclohexenyl, fused cyclopentyl or fused 2,3-furyl.

25


This invention further includes the aforementioned compound wherein R₁ is methyl or ethyl;

wherein R_2 is H or fused benzene;

wherein R_3 is cyclohexyl, pentoxy, phenoxy, trifluoromethyl ether, methylbenzene ether, 4-hydroxypentyl, or wherein R_2 and R_3 and the carbons to which they are attached form fused 5,6-cyclohexenyl, fused cyclopentyl, or fused 2,3-furyl;

wherein R_4 is H, 1-hydroxyethyl, trifluoromethyl ether, or wherein R_3 and R_4 and the carbons to which they are attached form fused 5,6-cyclohexenyl, fused cyclopentyl or fused 2,3-furyl.


This invention further includes the compound having the structure:



wherein R_3 is straight chained C_3 , C_4 , C_6 or C_7 alkyl or branched C_5 - C_7 alkyl or aryl.

This invention further includes the aforementioned compound wherein R_3 is butyl, hexyl, heptyl, or benzyl.

This invention further includes the compound having the structure:



wherein X = CH, C(CH₃) or N;

wherein each of R₁, R₂, R₃, R₄ and R₅ is independently H, C₁-C₁₀ straight chained or branched alkyl, C₂-C₁₀ straight chained or branched alkenyl, C₂-C₁₀ straight chained or branched alkynyl, C₃-C₁₀ cycloalkyl, substituted or unsubstituted aryl, hydroxy, halogenated ether, nitro, amino, halogen, -CN, -C(=Z)R₆, -C(=Z)OR₆, -C(=Z)N(R₆)₂, -N(R₆)-C(=Z)R₆, -N(R₆)-C(=Z)N(R₆)₂, -OC(=Z)R₆, -C(=Z)OR₆ -OR₆ or -SR₆;

wherein Z is O or S; and

wherein R₆ is C₁-C₁₀ straight chained or branched alkyl, aryl, (CH₂)_nQ, C₂-C₁₀ alkenyl, C₃-C₁₀ cycloalkyl, C₅-C₁₀ cycloalkenyl,

wherein Q is OR₇, SR₇, N(R₇)₂ or aryl,

wherein R₇ is H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl,

wherein R₂ and R₃ and the carbons to which they are attached form a fused aryl, heteroaryl, C₅-C₁₀ cyclic alkyl or heterocyclic alkyl ring; or wherein R₃ and R₄ and the carbons to which they are attached form a fused aryl, heteroaryl,

cyclic alkyl or heterocyclic alkyl ring;

and wherein each alkyl, alkenyl, alkynyl and alkoxy group is optionally substituted with a substituent independently

5 selected from R_a , where R_a is

- 1) hydroxy,
- 2) C_1 - C_{10} alkoxy,
- 3) halogen,
- 4) nitro,
- 10 5) amino,
- 6) CF_3 , or
- 7) carboxy,

and each cycloalkyl group is optionally substituted with a substituent independently selected from R_b , where R_b is

- 15 1) a group selected from R_a ,
- 2) C_1 - C_7 alkyl,
- 3) C_2 - C_7 alkenyl,
- 4) C_2 - C_7 alkynyl or
- 20 5) cyclic C_1 - C_{10} alkyl,

and each aryl is optionally substituted with R_1 , and

wherein each R_6 and R_7 is independently acetate, formate, phosphate ester, dimethylglycine ester, aminoalkylbenzyl ester, aminoalkyl ester and carboxyalkyl ester.

This invention further includes the aforementioned compound wherein R_6 and R_7 is independently

acetyl or acyl.

This invention provides a pharmaceutical composition comprising any of the aforementioned compounds together with
5 a pharmaceutically acceptable carrier.

This invention further provides a method of preparing a pharmaceutical composition comprising mixing the compound of any of the aforementioned compounds with a pharmaceutical
10 acceptable carrier.

This invention further provides a compound which is converted in vivo to the compound of any of the aforementioned compounds.
15

This invention further provides a compound which is a metabolite of the compound of any of the aforementioned compounds

20 This invention further provides a salt of the compound of any of the aforementioned compounds.

For certain compounds, enantiomers, diastereomers, double bond stereoisomers and double bond regioisomers exist. This
25 invention contemplates racemic mixtures as well as isolated enantiomers, double bond stereoisomers, double bond regioisomers and diastereomers.

The invention provides for each pure stereoisomer of any of

the compounds described herein. Such stereoisomers may include enantiomers, diastereomers, or E or Z alkene isomers. The invention also provides for stereoisomeric mixtures, including racemic mixtures, diastereomeric mixtures, or E/Z isomeric mixtures. Stereoisomers can be synthesized in pure form (Nógrádi, M.; Stereoselective Synthesis, (1987) VCH Editor Ebel, H. and Asymmetric Synthesis, Volumes 3 - 5, (1983) Academic Press, Editor Morrison, J.) Or they can be resolved by a variety of methods such as crystallization and chromatographic techniques (Jaques, J.; Collet, A.; Wilen, S.; Enantiomer, Racemates, and Resolutions, 1981, John Wiley and Sons and Asymmetric Synthesis, Vol. 2, 1983, Academic Press, Editor Morrison, J).

In addition the compounds of the present invention may be present as enantiomers, diastereomers, isomers or two or more of the compounds may be present to form a racemic or diastereomeric mixture.

The compounds of the present invention are preferably 80% pure, more preferably 90% pure, and most preferably 95% pure.

As used herein, the term aryl is used to include phenyl, benzyl, or naphthyl, and the term heteroaryl is used to include pyrazinyl, imidazolyl, imidazoliny, indolyl, benzimidazolyl, benzofuranyl, pyrimidinyl, benzothiophenyl, isoquinolyl, or quinolyl. The term arylalkyl is used to designate an C1-C6 alkyl chain substituted with an aryl group and the term heteroarylalkyl is used to designate a C1-C6

alkyl chain substituted with a heteroaryl group.

In the present invention, the term "heteroaryl" is used to include five and six membered unsaturated rings that may contain one or more oxygen, sulfur, or nitrogen atoms. Examples of heteroaryl groups include, but are not limited to, furanyl, thienyl, pyrrolyl, oxazolyl, thiasolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, and triazinyl.

In addition the term "heteroaryl" is used to include fused bicyclic ring systems that may contain one or more heteroatoms such as oxygen, sulfur and nitrogen. Examples of such heteroaryl groups include, but are not limited to, indolizinyl, indolyl, isoindolyl, benzo[b]furanyl, benzo[b]thiophenyl, indazolyl, benzimidazolyl, purinyl, benaoxazolyl, benzisoxazolyl, benzo[b]thiazolyl, imidazo[2,1-b]thiazolyl, cinnolinyl, quinasolinyl, quinoxalinyl, 1,8-naphthyridinyl, pteridinyl, quinolinyl, isoquinolinyl, phthalimidyl and 2,1,3-benzothiazolyl.

Heterocyclic is defined as a 3 to 10 atom-ring containing at least one saturated bond and containing in any position one or more of the following atoms: N,O,S. Examples of heterocyclic rings include but are not limited to tetrahydrofuran, dihydrofuran, tetrahydropyran, dihydropyran, piperidine, dihydropiperidine, pyrrolidine, dihydropyrrolidine, dioxane, piperazin.

The compounds of invention herein are the first known small molecule (non-peptide/non-peptoid) ligands (either antagonists or agonists) at the neuropeptide FF(NPFF) receptor(s).

5

In separate embodiments, the abnormality is a lower urinary tract disorder such as interstitial cystitis or urinary incontinence such as urge incontinence or stress incontinence particularly urge incontinence, a regulation of a steroid hormone disorder, an epinephrine release disorder, a gastrointestinal disorder, irritable bowel syndrome, a cardiovascular disorder, an electrolyte balance disorder, diuresis, hypertension, hypotension, diabetes, hypoglycemia, a respiratory disorder, asthma, a reproductive function disorder, an immune disorder, an endocrine disorder, a musculoskeletal disorder, a neuroendocrine disorder, a cognitive disorder, a memory disorder, a sensory modulation and transmission disorder, a motor coordination disorder, a sensory integration disorder, a motor integration disorder, a dopaminergic function disorder, an appetite disorder, obesity, a serotonergic function disorder, an olfaction disorder, a sympathetic innervation disorder, an affective disorder, pain, psychotic behavior, morphine tolerance, nicotine addiction, opiate addiction, or migraine.

25

As used herein, the phrase "pharmaceutically acceptable carrier" means any of the standard pharmaceutically acceptable carriers. Examples include, but are not limited to, phosphate buffered saline, physiological saline, water, and emulsions,

such as oil/water emulsions.

The formulations of the present invention can be solutions, suspensions, emulsions, syrups, elixirs, capsules, tablets, and the like. The compositions may contain a suitable carrier, diluent, or excipient, such as sterile water, physiological saline, glucose, or the like. Moreover, the formulations can also be lyophilized, and/or may contain auxiliary substances, such as wetting or emulsifying agents, pH buffering agents, adjuvants, gelling or viscosity enhancing additives, preservatives, flavoring agents, colors, and the like, depending upon the route of administration and the preparation desired. Standard texts, such as "Remington's Pharmaceutical Science", 17th Ed., 1985, incorporated herein by reference, may be consulted to prepare suitable preparations, without undue experimentation.

The formulations can include powdered carriers, such as lactose, sucrose, mannitol, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like. Further, tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of hours. Compressed tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric coated for selective disintegration in the gastrointestinal tract. The formulations can also contain coloring and flavoring to enhance patient acceptance. The formulations can also include any of disintegrants, lubricants, plasticizers, colorants, and dosing

vehicles.

In general, water, a suitable oil, saline, aqueous dextrose (glucose), and related sugar solutions and glycols such as propylene glycol or polyethylene glycols such as propylene glycol or polyethylene glycols are suitable carriers for parenteral solutions. Solutions for parenteral administration contain preferably a water soluble salt of the active ingredient, suitable stabilizing agents, and, if necessary, buffer substances.

Antioxidants such as, for example, sodium bisulfate, sodium sulfite, citric acid and its salts, sodium EDTA, ascorbic acid, and the like can be used either alone or in combination with other suitable antioxidants or stabilizing agents typically employed in the pharmaceutical compositions. In addition, parenteral solutions can contain preservatives, such as, for example, benzalkonium chloride, methyl- or propylparaben, chlorobutanol and the like.

The present invention includes within its scope prodrugs of the compounds of this inventions. In general, such prodrugs will be functional derivatives of the compounds of the invention which are readily convertible in vivo into the required compound.

Thus, in the methods of treatment of the present invention, the term "administering" shall encompass the treatment of the

various conditions described with the compound specifically disclosed or with a compound which may not be specifically disclosed, but which converts to the specified compound in vivo after administration to the patient. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in Design of Prodrugs, ed. H. Bundgaard, Elsevier, 1985, the content of which is incorporated into the subject description by reference.

10

Included in this invention are pharmaceutically acceptable salts and complexes of all of the compounds described herein. The salts include, but are not limited to, the following acids and bases: Inorganic acids which include hydrochloric acid, hydrofluoric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, and boric acid; organic acids which include acetic acid, trifluoroacetic acid, formic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, maleic acid, citric acid, methanesulfonic acid, trifluoromethanesulfonic acid, benzoic acid, glycolic acid, lactic acid, and mandelic acid; inorganic bases include ammonia and hydrazine; and organic bases which include methylamine, ethylamine, hydroxyethylamine, propylamine, dimethylamine, diethylamine, trimethylamine, triethylamine, ethylenediamine, hydroethylamine, morpholine, piperazine, and guanidine.

20

25

This invention further provides for the hydrates and

polymorphs of all of the compounds described herein.

The present invention further includes metabolites of the compounds of the present invention. Metabolites include active
5 species produced upon introduction of compounds of this invention into the biological milieu.

One skilled in the art will readily appreciate that appropriate biological assays will be used to determine the
10 therapeutic potential of the claimed compounds for treating the above noted disorders.

This invention will be better understood from the Experimental Details which follow. However, one skilled in the art will
15 readily appreciate that the specific methods and results discussed are merely illustrative of the invention as described more fully in the claims which follow thereafter.

EXPERIMENTAL DETAILS

I. Synthesis of Chemical Compounds


5 General Methods:

All reactions were performed under an inert atmosphere (Argon) and the reagents, neat or in appropriate solvents, were transferred to the reaction vessel via syringe and cannula techniques. The parallel synthesis reaction arrays were performed in vials (without an inert atmosphere) using J-KEM heating shakers (Saint Louis, MO). Anhydrous solvents (i.e. tetrahydrofuran, toluene and 1-methyl-2-pyrrolidinone) were purchased from Aldrich Chemical Company (Milwaukee, WI) and used as received. The compounds described in this patent were named using ACD/Name program (version 2.51, Advanced Chemistry Development Inc., Toronto, Ontario, M5H2L3, Canada). ¹H and ¹³C spectra were recorded at 300 and 75 MHz (QE-300 Plus by Bruker Instruments, Billerica, MA). Chemical shifts are reported in parts per million (ppm) and referenced with respect to the residual (i.e. CHCl₃, CH₃OH) proton of the deuterated solvent. Splitting patterns are designated as s = singlet; d = doublet; t = triplet; q = quartet; p = quintet; sextet; septet; broad = br; m = multiplet. Elemental analyses were performed by Robertson Microlit Laboratories, Inc. (Madison, NJ) Low-resolution electrospray mass spectra (ESMS) were measured and MH⁺ is reported. Thin-layer chromatography (TLC) was carried out on glass plates precoated with silica gel 60 F₂₅₄ (0.25 mm,

EM Separations Tech.). Preparative TLC was carried out on glass sheets precoated with silica gel GF (2 mm, Analtech, Newark, DE). Flash column chromatography was performed on Merck silica gel 60 (230 - 400 mesh).


5

The following (Scheme 1) is a representative synthetic scheme for the synthesis of quinazolino-guanidines (32, 33a, b).



59

An alternative route (34) for the synthesis of quinazolino-guanidines is illustrated below (Scheme 2).




5

Scheme 2

10

The following (Scheme 3) is a representative synthetic scheme for the synthesis of quinolino-guanidines (35).



Example 1

The following is a representative example of Methods A - C in Scheme 1 for the synthesis of N-(6,7-dibutoxy-4-methyl-2-quinazolinyl)guanidine (Compound 1018).

Method A (Ref #1):

In a flask equipped with a magnetic stirrer, 1,2-dibutoxy-4-nitrobenzene (500 mg, 1.87 mmol) was dissolved in methyl alcohol (23 mL). To this stirring solution was added a saturated aqueous solution of copper (II) acetate (7.5 mL) followed by sodium borohydride (779 mg, 20.6 mmol) added in several small portions so as keep the reaction solution from bumping. After all the sodium borohydride had been added, the solution was allowed to stir at room temperature (r.t.) for an additional 2 h. Brine (100 mL) was added followed by extraction of the aqueous phase with ethyl ether (2x) in a separatory funnel. The combined ethereal extracts were washed with saturated aqueous sodium bicarbonate. The ether was evaporated and the crude material further purified by silica column chromatography eluting with 50% ethyl acetate in hexane ($R_f = 0.20$). The fractions were combined and solvent evaporated to afford 323 mg (73% yield) of 3,4-dibutoxyaniline.

Method B (Ref #2):

In a flask equipped with a magnetic stirrer, 3,4-dibutoxyaniline (323 mg, 1.36 mmol) was dissolved in acetone
5 (2.3 mL). To this stirring solution was added magnesium sulfate (5.0 eq, 819 mg, 6.80 mmol), tert-butylcatechol (0.03 eq, 7 mg, 0.04 mmol) and iodine (0.05 eq, 17 mg, 0.07 mmol), in that order. The solution was refluxed for 8 h. Upon cooling to r.t., the solution was filtered and the residue
10 further washed with methyl alcohol. The residue was purified by silica column chromatography eluting with 25% ethyl acetate in hexane to afford 230 mg (53% yield) of 6,7-dibutoxy-2,2,4-trimethyl-1,2-dihydroquinoline.

15 Method C:

In a flask equipped with a magnetic stirrer, 6,7-dibutoxy-2,2,4-trimethyl-1,2-dihydroquinoline (230 mg, 0.72 mmol) was dissolved in 0.5 mL of a solution made up of 0.1 mL of 37%
20 aqueous hydrochloric acid + 0.4 mL of water. This solution was refluxed for 1 h. Upon cooling to r.t., 1.5 mL of a 2.0 M ammonia solution in methyl alcohol was added followed by evaporation of the solvent. Purification via preparative TLC eluting with 25% methyl alcohol (containing 2.0 M of ammonia)
25 in chloroform afforded, after isolation of the desired spots (Rf = 0.2), 63 mg (25% yield) of N-(6,7-dibutoxy-4-methyl-2-

quinazolinyl)guanidine.

Name: 6,7-dibutoxy-2,2,4-trimethyl-1,2-dihydroquinoline.
(synthesized using Method B (53% yield)).

5 Data: ESMS 318 (MH⁺); ¹H NMR (CDCl₃) δ 6.70 (br s, 1H), 6.07
(br s, 1H), 5.19 (br s, 1H), 3.93 (br s, 4H), 1.94 (br s, 3H),
1.75 (septet, 4H, J = 7.8 Hz), 1.48 (septet, 4H, J = 7.5 Hz),
1.24 (s, 6H), 0.962 (t, 3H, J = 7.2 Hz), 0.958 (t, 3H, J = 7.2
Hz).

10

Compound 1018 (synthesized using Method C (25% yield))

Name: N-(6,7-dibutoxy-4-methyl-2-quinazolinyl)guanidine

15 Data: ESMS 246 (MH⁺); ¹H NMR (CD₃OD) δ 7.89 (br s, 2H), 7.21
(br s, 1H), 7.16 (br s, 1H), 4.13 (t, 2H, J = 6.3 Hz), 4.08
(t, 2H, J = 6.3 Hz), 2.76 (br s, 3H), 1.88-1.80 (m, 4H), 1.56
(septet, 4H, J = 7.5 Hz), 1.013 (t, 3H, J = 7.5 Hz), 1.008 (t,
3H, J = 7.2 Hz).

Example 2

20

The following is a representative example of Methods D - F in
Scheme 2 for the synthesis of N-(4-methyl-2-
quinazolinyl)guanidine (Compound 1001).

Method D:

In a flask equipped with a magnetic stirrer, a solution of 6-bromo-2-fluorobenzoic acid (1.00g, 4.57 mmol) dissolved in anhydrous ethyl ether (7 mL) was cooled to -78°C using a dry ice-acetone bath. Methyl lithium was then added dropwise (6.8 mL of a 1.4 M solution in ethyl ether, 9.59 mmol). The reaction was further stirred at -78°C for 5 min followed by warming to r.t. by removing the dry ice-acetone bath. After stirring for an additional 30 min at r.t., the solution was poured into a mixture of ice and saturated aqueous solution of ammonium chloride. The aqueous phase was extracted with ethyl ether twice and the combined ethereal extracts washed with brine. The organic phase was dried with anhydrous sodium sulfate, filtered and solvent evaporated. Purification by silica column chromatography eluting with 5% ethyl acetate in hexane ($R_f = 0.4$) afforded 194 mg (20% yield) of 1-(5-bromo-2-fluorophenyl)ethanone.

20 Method E:

In a flask equipped with a magnetic stirrer, 1-(5-bromo-2-fluorophenyl)ethanone (517 mg, 2.36 mmol) was dissolved in 1-methyl-2-pyrrolidinone (NMP) (3.4 mL). Dicyandiamide (2.0 eq, 397 mg, 4.72 mmol) and potassium carbonate (1.0 eq, 326 mg, 2.36 mmol) were added to the solution and the reaction was

heated at 120°C for 4 h. Upon cooling the reaction to r.t., the solution was filtered and the residue extracted further with methyl alcohol. The methyl alcohol was evaporated. The NMP solution was placed directly on a silica column eluting
5 with 20% methyl alcohol (containing 2.0 M ammonia) in chloroform. Fractions containing the product ($R_f = 0.5$ with 5% methyl alcohol in ethyl acetate) were combined and solvent evaporated to afford 109 mg (18% yield) of 6-bromo-4-methyl-2-quinazolinylcyanamide.

10

Method F:

To a suspension of ammonium chloride (53.5 mg, 1 mmol) in toluene (1 mL) at r.t. was added 0.5 mL of a 2.0 M
15 trimethylaluminum chloride suspended in toluene (1 mmol). The resulting suspension was stirred at r.t. for 2 h followed by the addition of 4-methyl-2-quinazolinylcyanamide (30 mg, 0.16 mmol). The mixture was heated at 80°C for 6 h. The reaction mixture was cooled and then poured into a slurry of silica gel
20 in chloroform. The suspension was stirred for 5 min and then filtered. The residue was further washed with methyl alcohol. Purification by preparative TLC eluting with 20% methyl alcohol (containing 2.0 M ammonia) in chloroform ($R_f = 0.1$) afforded *N*-(4-methyl-2-quinazolinyl)guanidine (11 mg, 34%
25 yield) after isolation of the product.

Compound 1001

Data: ESMS 202 (MH⁺); ¹H NMR (CD₃OD) δ 8.15 (d, J = 8.1, Hz, 1H), 7.80-7.90 (m, 2H), 7.52-7.58 (m, 1H), 2.89 (s, 3H).

5 Example 3

The following is a representative example of Methods G - J in Scheme 3 for the synthesis of N-(6-ethyl-4-methyl-2-quinolinyl)guanidine (Compound 4002).

10

Method G:

To a flask equipped with a magnetic stirrer was added 4-ethyl-
aniline (9.75 g, 80.5 mmol), toluene (20 mL) and methyl
15 acetoacetate (9.1 mL, 85.4 mmol). The reaction mixture was
heated to reflux using a Dean-Stark apparatus for 1 h, when
the amount of methyl alcohol collected in the apparatus ceased
to increase. Upon cooling to r.t., the solvent was evaporated
using rotary-evaporator. The crude material was purified by
20 silica column chromatography eluting with 10% methyl alcohol
(containing 2.0 M ammonia) in chloroform (R_f = 0.6) to afford
5.1 g of N-(4-ethylphenyl)-3-oxobutanamide (31% yield).

Method H:

A flask equipped with a magnetic stirrer containing concentrated sulfuric acid (50 mL) was cooled to 0°C with an ice-bath followed by the addition of water (25 mL). The solution was heated to 80°C and N-(4-ethylphenyl)-3-oxobutanamide (5.1 g, 24.8 mmol) added. This solution was stirred and heated at 120°C for 0.5 h. The reaction was then cooled to r.t. and added to a flask containing ice and water (323 mL). Upon standing overnight in water, crystals formed and were collected via filtration. The crystals were dissolved in a minimum amount of methyl alcohol and filtered through a short pad of silica eluting with 10% methyl alcohol (containing 2.0 M of ammonia) in chloroform. Evaporation of the solvent afforded 3.06 g (66% yield) of 6-ethyl-4-methyl-2(1H)-quinolinone.

15

Method I:

To a flask equipped with a magnetic stirrer were added 6-ethyl-4-methyl-2(1H)-quinolinone (3.06 g, 16.3 mmol) and phosphorus oxychloride (16.3 mL, 16.3 mmol). The mixture was refluxed for 18 h.) The solution was cooled to r.t. and poured into ice water (163 mL) and neutralized to pH = 7 using 6 N NaOH (aq). The aqueous phase was extracted with methylene chloride (3x). The organic phase was then filtered through a short pad of silica eluting with methylene chloride. Evaporation of the solvent afforded 2.60 g (77% yield) of 2-chloro-6-ethyl-4-methylquinoline.

25

Method J

To a flask equipped with a magnetic stirrer were added 2-chloro-6-ethyl-4-methylquinoline (2.02 g, 9.81 mmol), 1-methyl-2-pyrrolidinone (41 mL), potassium carbonate (3.12 g, 22.6 mmol) and guanidine hydrochloride (1.12 g, 11.8 mmol). The mixture was heated at 140°C for 12 h. Upon cooling to r.t., the mixture was filtered and the residue further extracted with methyl alcohol. The filtrates were combined and the solvent evaporated. The crude material was purified by reverse phase HPLC to afford 46 mg (1% yield) of *N*-(6-ethyl-4-methyl-2-quinolinyl)guanidine as the trifluoroacetate salt.

15 Name: *N*-(4-ethylphenyl)-3-oxobutanamide. (synthesized using Method G (31% yield)).

Data: ESMS 206 (MH⁺); ¹H NMR (CD₃OD) δ 7.42 (d, 2H, J = 8.4 Hz), 7.13 (d, 2H, J = 8.4 Hz), 3.29 (s, 2H), 2.59 (q, 2H, J = 7.8 Hz), 2.25 (s, 3H), 1.19 (t, 3H, J = 7.5 Hz).

20

Name: 6-ethyl-4-methyl-2(1H)-quinolinone. (synthesized using Method H (66% yield)).

Data: ESMS 188 (MH⁺); ¹H NMR (CDCl₃) δ 7.55 (s, 1H), 7.50 (d, 1H, J = 8.4 Hz), 7.47 (d, 1H, J = 8.4 Hz), 6.69 (s, 1H), 2.77 (q, 2H, J = 7.8 Hz), 2.59 (s, 3H), 1.30 (t, 3H, J = 7.8 Hz).

25

Name: 2-chloro-6-ethyl-4-methylquinoline (synthesized using Method I (77% yield)).

Data: ESMS 208 & 206 (MH⁺); ¹H NMR (CD₃OD) δ 7.80 (br d, 1H, J = 8.7 Hz), 7.63 (dd, 1H, J = 8.7, 1.8 Hz), 7.29 (d, 1H, J = 0.6 Hz), 2.84 (q, 2H, J = 7.5 Hz), 2.66 (d, 3H, J = 0.9 Hz), 1.31 (t, 3H, J = 7.5 Hz).

Compound 4002 (class: Quinolino-guanidine; synthesized using Method J).

10 Name: N-(6-ethyl-4-methyl-2-quinolinyl)guanidine.

Data: ESMS 229 (MH⁺); ¹H NMR (CD₃OD) δ 7.77 (br d, 1H, J = 8.7 Hz), 7.57 (dd, 1H, J = 8.7, 1.8 Hz), 6.90 (d, 1H, J = 0.6 Hz), 2.81 (q, 2H, J = 7.5 Hz), 2.64 (d, 3H, J = 0.6 Hz), 1.30 (t, 3H, J = 7.5 Hz).

15

Example 4

Compound 3001 (Purchased from Tripos (St. Louis, MO)).

Name: N-(4,7-dimethyl-2-quinazolinyl)guanidine.

20

Example 5

Compound 1007 (class: Quinazolino-guanidine; Purchased from

70

Sigma).

Name: *N*-(1-methylbenzo[f]quinazolin-3-yl)guanidine.

Example 6

5

N-(4-methyl-2-quinolinyl)guanidine is made in the same manner as *N*-(6-ethyl-4-methyl-2-quinolinyl)guanidine (see Example 3) except that 2-chloro-4-methylquinoline is used in place of 2-chloro-6-ethyl-4-methylquinoline.

10

Compound 6001 (class: Quinolino-guanidine; synthesized using Method J (67% yield))

Name: *N*-(4-methyl-2-quinolinyl)guanidine.

15 Data: ESMS 201 (MH⁺); ¹H NMR (CD₃OD) δ 7.86 (d, *J* = 8.1 Hz, 1H), 7.70 (d, *J* = 8.4 Hz, 1H), 7.52-7.59 (m, 1H), 7.32-7.38 (m, 1H), 6.80 (s, 1H), 2.57 (s, 3H); Anal. (C₁₁H₁₂N₄ · 0.15 CHCl₃) calcd, C 61.39, H 5.61, N 25.68; Found, C 61.81, H 5.40, N 26.36.

20 Example 7

N-(4,7-dimethyl-2-quinolinyl)guanidine is made in the same manner as *N*-(6-ethyl-4-methyl-2-quinolinyl)guanidine (see

Example 3) except that 3-methylaniline is used in place of 4-ethylaniline.

Compound 4006 (Class: Quinolono-guanidine; synthesized using
5 Method J (17% yield))

Name: *N*-(4,7-dimethyl-2-quinolinyl)guanidine.

Data: ESMS 215 (MH⁺); ¹H NMR (CD₃OD) δ 7.89 (d, *J* = 8.5 Hz, 1H), 7.67 (s, 1H), 7.37 (dd, *J* = 8.5, 1.6 Hz, 1H), 6.88 (s, 1H), 2.65 (s, 3H), 2.51 (s, 3H).

10

Example 8

N-(4-ethyl-7-methyl-2-quinolinyl)guanidine is made in the same manner as *N*-(6-ethyl-4-methyl-2-quinolinyl)guanidine (see
15 Example 3) except that 3-methylaniline is used in place of 4-ethylaniline and methyl-3-oxopentanoate in place of methyl acetoacetate.

Compound 6003 (class: Quinolono-guanidine; synthesized using
20 Method J (9% yield))

Name: *N*-(4-ethyl-7-methyl-2-quinolinyl)guanidine.

Data: ESMS 229 (MH⁺); ¹H NMR (CD₃OD) δ 7.92 (d, *J* = 8.6 Hz, 1H), 7.68 (s, 1H), 7.37 (dd, *J* = 8.5, 1.7 Hz, 1H), 6.90 (s, 1H), 3.07 (q, *J* = 7.2 Hz, 2H), 2.51 (s, 3H), 1.36 (t, *J* = 7.5

Hz, 3H) .

Example 9

5 *N*-(4,8-dimethyl-2-quinolinyl)guanidine is made in the same manner as *N*-(6-ethyl-4-methyl-2-quinolinyl)guanidine (see Example 3) except that 2-chloro-4,8-dimethylquinoline is used in place of 2-chloro-6-ethyl-4-methylquinoline.

10 Compound 6002 (class: Quinolono-guanidine; synthesized using Method J (20% yield))

Name: *N*-(4,8-dimethyl-2-quinolinyl)guanidine.

Data: ESMS 215 (MH⁺); ¹H NMR (CD₃OD) δ 7.84 (d, *J* = 8.1 Hz, 1H), 7.57 (d, *J* = 7.2 Hz, 1H), 7.41 (dd, *J* = 8.1, 7.2 Hz, 1H),
15 6.94 (d, *J* = 0.6 Hz, 1H), 2.66 (s, 3H), 2.56 (s, 3H) .

Example 10

20 *N*-(6-chloro-4-methyl-2-quinolinyl)guanidine is made in the same manner as *N*-(6-ethyl-4-methyl-2-quinolinyl)guanidine (see Example 3) except that 2,6-dichloro-4-methylquinoline is used in place of 2-chloro-6-ethyl-4-methylquinoline.

Compound 4005 (class: Quinolino-guanidine; synthesized using Method J (42-71% yield)).

Name: *N*-(6-chloro-4-methyl-2-quinolinyl)guanidine.

5 Data: ESMS 231 (MH⁺); ¹H NMR (CD₃OD) δ 7.80 (d, *J* = 2.4 Hz, 1H), 7.88 (d, *J* = 8.7 Hz, 1H), 7.66 (dd, *J* = 9.0, 2.4 Hz, 1H), 7.00 (d, *J* = 0.9 Hz, 1H), 2.65 (s, 3H); Anal. (C₁₁H₁₁ClN₄ + 0.1 CHCl₃ · 0.7 H₂O) calcd, C 51.43, H 4.86, N 21.61; Found, C 51.41, H 4.85, N 21.78.

10 Example 11

N-(1-methylbenzo[f]quinolin-3-yl)guanidine is made in the same manner as *N*-(6-ethyl-4-methyl-2-quinolinyl)guanidine (see Example 3) except that 3-chloro-1-methylbenzo[f]quinoline is
15 used in place of 2-chloro-6-ethyl-4-methylquinoline.

Compound 4009 (class: Quinolino-guanidine; synthesized using Method J (21% yield))

Name: *N*-(1-methylbenzo[f]quinolin-3-yl)guanidine.

20 Data: ESMS 251 (MH⁺); ¹H NMR (CD₃OD) δ 8.63 (d, *J* = 7.8 Hz, 1H), 7.83-7.87 (m, 2H), 7.46-7.63 (m, 3H), 6.91 (s, 1H), 2.93 (s, 3H).

Example 12

N-(6-methoxy-4-methyl-2-quinolinyl)guanidine is made in the same manner as *N*-(6-ethyl-4-methyl-2-quinolinyl)guanidine (see Example 3) except that 2-chloro-6-methoxy-4-methylquinoline is used in place of 2-chloro-6-ethyl-4-methylquinoline.

5

Compound 4004 (class: Quinolono-guanidine; synthesized using Method J (13% yield)).

Name: *N*-(6-methoxy-4-methyl-2-quinolinyl)guanidine.

Data: ESMS 231 (MH⁺); ¹H NMR (CD₃OD) δ 7.80 (d, *J* = 9.3 Hz, 1H), 7.34 (dd, *J* = 9.0, 2.7 Hz, 1H), 6.98 (d, *J* = 0.9 Hz, 1H), 3.92 (s, 3H), 2.65 (s, 3H).

Example 13

15 *N*-(4,5,7-trimethyl-2-quinolinyl)guanidine is made in the same manner as *N*-(6-ethyl-4-methyl-2-quinolinyl)guanidine (see Example 3) except that 3,5-dimethylaniline is used in place of 4-ethylaniline.

20 Compound 4008 (class: Quinolono-guanidine; synthesized using Method J (7% yield)).

Name: *N*-(4,5,7-trimethyl-2-quinolinyl)guanidine.

Data: ESMS 229 (MH⁺); ¹H NMR (CD₃OD) δ 7.51 (s, 1H), 7.13 (s, 1H), 6.80 (s, 1H), 2.85 (s, 3H), 2.82 (s, 3H), 2.42 (s, 3H).

Example 14

N-(4,6-dimethyl-2-quinolinyl)guanidine is made in the same manner as *N*-(6-ethyl-4-methyl-2-quinolinyl)guanidine (see Example 3) except that 4-methylaniline is used in place of 4-ethylaniline.

Compound 4001 (class: Quinolono-guanidine; synthesized using Method J (5% yield)).

10 Name: *N*-(4,6-dimethyl-2-quinolinyl)guanidine.

Data: ESMS 215 (MH⁺); ¹H NMR (CD₃OD) δ 7.79 (dd, *J* = 4.2, 4.2 Hz, 2H), 7.89 (dd, *J* = 8.7, 1.8 Hz, 1H), 7.75 (d, *J* = 0.9 Hz, 1H), 2.67 (d, *J* = 0.9 Hz, 3H), 2.52 (s, 3H).

15 Example 15

N-(4-methyl-6-phenyl-2-quinolinyl)guanidine is made in the same manner as *N*-(6-ethyl-4-methyl-2-quinolinyl)guanidine (see Example 3) except that 2-chloro-4-methyl-6-phenylquinoline is used in place of 2-chloro-6-ethyl-4-methylquinoline.

Compound 4003 (class: Quinolono-guanidine; synthesized using Method J (28% yield)).

76

Name: *N*-(4-methyl-6-phenyl-2-quinolinyl)guanidine.

Data: ESMS 277 (MH⁺); ¹H NMR (CD₃OD) δ 8.10 (d, *J* = 1.2 Hz, 1H), 7.90-7.98 (m, 2H), 7.65-7.73 (m, 2H), 7.32-7.50 (m, 3H), 7.01 (s, 1H), 2.73 (s, 3H).

5

Example 16

N-(7-ethyl-4-methyl-2-quinazolinyl)guanidine is made in the same manner as *N*-(6-ethyl-4-methyl-2-quinolinyl)guanidine (see
10 Example 3) except that 3-ethylaniline is used in place of 4-ethylaniline.

Compound 1020 (class: Quinazolino-guanidine; synthesized using Method C (52% yield)).

15 Name: *N*-(7-ethyl-4-methyl-2-quinazolinyl)guanidine.

Data: ESMS 230 (MH⁺); ¹H NMR (CD₃OD) δ 8.09 (d, *J* = 8.4 Hz, 1H), 7.68 (d, *J* = 0.9 Hz, 1H), 7.49 (dd, *J* = 8.4, 1.5 Hz, 1H), 2.88 (s, 3H), 2.86 (q, *J* = 7.6 Hz, 2H), 1.32 (t, *J* = 7.5 Hz, 3H).

20

Example 17

N-(7-fluoro-4-methyl-2-quinolinyl)guanidine is made in the

same manner as *N*-(6-ethyl-4-methyl-2-quinolinyl)guanidine (see Example 3) except that 3-fluoroaniline is used in place of 4-ethylaniline.

- 5 Compound 4007 (class: Quinolino-guanidine; synthesized using Method J (36% yield)).

Name: *N*-(7-fluoro-4-methyl-2-quinolinyl)guanidine.

- 10 Data: ESMS 219 (MH⁺); ¹H NMR (CD₃OD) δ 8.00 (dd, *J* = 9.0, 6.0 Hz, 1H), 7.57 (dd, *J* = 10.2, 2.4 Hz, 1H), 7.30 (dt, *J* = 8.7, 2.7 Hz, 1H), 6.88 (s, 1H), 2.64 (s, 3H); Anal. (C₁₁H₁₁FN₄ 1.1 CF₃CO₂H) calcd, C 46.13, H 3.55, N 16.30; Found, C 46.66, H 3.31, N 16.41.

Example 18

15

Compound 1002 (class: Quinazolino-guanidine).

Name: *N*-(4,6-dimethyl-2-quinazolinyl)guanidine.

- 20 A compound purchased from Tripos was found to have the wrong structure assignment and to contain an impurity. Tripos' incorrect structure assignment was 2-[(4,7-dimethyl-2-quinazolinyl)amino]-4-quinazolinol. By NMR and MS techniques, the sample was determined to be a mixture of *N*-(4,6-dimethyl-2-quinazolinyl) guanidine and methyl 2-aminobenzoate, which was separated by preparative TLC to afford pure *N*-(4,6-
- 25 dimethyl-2-quinazolinyl)guanidine.

Data: ESMS 216 ($MH^+ - NH_3$); 1H NMR (CD_3OD) δ 7.97 (s, 1H), 7.77 (br s, 2H, 2nd Order Coupling), 2.89 (s, 3H), 2.54 (s, 3H); ^{13}C NMR (CD_3OD) 172.2, 156.4, 153.4, 147.8, 137.7, 137.6, 127.0, 124.9, 122.1, 21.0, 20.7.

5

Example 19

N-(6,7-difluoro-4-methyl-2-quinazolinyl)guanidine is made in the same manner as *N*-(6,7-dibutoxy-4-methyl-2-quinazolinyl)guanidine (see Example 1, steps B and C) except
10 that 3,4-difluoroaniline is used in place of 3,4-dibutoxyaniline.

Compound 1019 (class: Quinolono-guanidine; synthesized using
15 Method J (42% yield)).

Name: *N*-(6,7-difluoro-4-methyl-2-quinazolinyl)guanidine.

Data: ESMS 238 (MH^+); 1H NMR (CD_3OD) δ 7.98 (dd, $J = 10.8, 8.7$ Hz, 1H), 7.59 (dd, $J = 11.4, 7.5$ Hz, 1H), 2.80 (s, 3H); Anal. ($C_{10}H_9F_2N_5 \cdot 0.21 SiO_2$) calcd, C 48.08, H 3.63, N 28.03; Found,
20 C 47.61, H 3.61, N 28.46.

Example 20

N-(7-bromo-4-methyl-2-quinazolinyl)guanidine is made in the

same manner as *N*-(6,7-dibutoxy-4-methyl-2-quinazolinyl)guanidine (see Example 1) except that 3-bromoaniline is used in place of 3,4-dibutoxyaniline.

- 5 Name: 7-bromo-2,2,4-trimethyl-1,2-dihydroquinoline
(Synthesized using Method B (28%)).

Data: ESMS 254 & 252 (MH⁺); ¹H NMR (CDCl₃) δ 6.88 (d, 1H, J = 8.1 Hz), 6.72 (dd, 1H, J = 8.1, 2.1 Hz), 6.57 (d, 1H, J = 2.1 Hz), 5.31 (br d, 1H, J = 1.2 Hz), 1.95 (d, 3H, J = 1.5 Hz),
10 1.27 (s, 6H).

Compound 1014 (class: Quinazolino-guanidine; synthesized using Method C (7% yield)).

Name: *N*-(7-bromo-4-methyl-2-quinazolinyl)guanidine.

- 15 Data: ESMS 282 & 280 (MH⁺); ¹H NMR (CD₃OD) δ 8.08 (d, 1H, 7.8 Hz), 7.88 (s, 1H), 7.69 (br d, 1H, J = 8.7 Hz), 2.89 (s, 3H).

Example 21

- 20 *N*-(6-bromo-4-methyl-2-quinazolinyl)guanidine is made in the same manner as *N*-(6,7-dibutoxy-4-methyl-2-quinazolinyl)guanidine (see Example 1) except that 4-bromoaniline is used in place of 3,4-dibutoxyaniline.

Name: 6-bromo-2,2,4-trimethyl-1,2-dihydroquinoline.

(Synthesized using Method B (22% yield)).

5 Data: ESMS 254 & 252 (MH⁺); ¹H NMR (CDCl₃) δ 7.12 (d, 1H, J = 2.1 Hz), 7.04 (dd, 1H, J = 8.4, 2.1 Hz), 6.31 (br d, 1H, J = 8.4 Hz), 5.33 (br s, 1H), 1.95 (d, 3H, J = 1.5 Hz), 1.26 (s, 6H).

10 Compound 1026 (class: Quinazolino-guanidine; synthesized using Methods C (4% yield)).

Name: N-(6-bromo-4-methyl-2-quinazolinyl)guanidine.

Data: ESMS 282 & 280 (MH⁺); ¹H NMR (CD₃OD) δ 8.40 (d, 1H, J = 2.1 Hz), 8.02 (dd, 1H, J = 8.7, 2.1 Hz), 7.85 (d, 1H, J = 9.0 Hz), 2.91 (s, 3H).

15

Example 22

20 N-[4-methyl-7-(trifluoromethoxy)-2-quinazolinyl]guanidine is made in the same manner as N-(6,7-dibutoxy-4-methyl-2-quinazolinyl)guanidine (see Example 1) except that 3-trifluoromethoxyaniline is used in place of 3,4-dibutoxyaniline.

Name: 2,2,4-trimethyl-7-(trifluoromethoxy)-1,2-

dihydroquinoline (Synthesized using Method B (29% yield)).

Data: ESMS 258 (MH⁺); ¹H NMR (CDCl₃) δ 7.00 (d, 1H, J = 8.1 Hz), 6.44 (dd, 1H, J = 7.5, 1.2 Hz), 6.26 (br s, 1H), 5.30 (d, 1H, J = 1.5 Hz), 1.96 (d, 3H, J = 1.5 Hz), 1.28 (s, 6H).

5

Compound 1036

Name: N-[4-methyl-7-(trifluoromethoxy)-2-quinazolinyl]guanidine (class: Quinazolino-guanidine; synthesized using Method C (5% yield)).

10 Data: ESMS 286 (MH⁺); ¹H NMR (CD₃OD) δ 8.26 (d, 1H, J = 9.3 Hz), 7.69 (br s, 1H), 7.39 (dm, 1H, J = 7.2 Hz), 2.89 (s, 3H):

Example 23

15 N-(6-chloro-4-methyl-2-quinazolinyl)guanidine is made in the same manner as N-(6,7-dibutoxy-4-methyl-2-quinazolinyl)guanidine (see Example 1) except that 4-chloroaniline is used in place of 3,4-dibutoxyaniline.

20 Compound 1013

Name: N-(6-chloro-4-methyl-2-quinazolinyl)guanidine (class: Quinazolino-guanidine; synthesized using Method C (35% yield)).

Data: ESMS 236 (MH⁺); ¹H NMR (CD₃OD) δ 8.20 (t, J = 1.5 Hz,

1H), 7.86 (d, $J = 1.5$ Hz, 2H), 2.89 (s, 3H); Anal. ($C_{10}H_{10}ClN_5 \cdot 0.21 CHCl_3 \cdot 0.7 H_2O$) calcd, C 44.86, H 4.28, N 25.62; Found, C 44.62, H 4.28, N 25.91.

5 Example 24

N-(6-methoxy-4-methyl-2-quinazolinyl)guanidine is made in the same manner as *N*-(6,7-dibutoxy-4-methyl-2-quinazolinyl)guanidine (see Example 1) except that 4-methoxyaniline is used in place of 3,4-dibutoxyaniline.

Compound 1011 (class: Quinazolino-guanidine; synthesized using Method C (13% yield)).

Name: *N*-(6-methoxy-4-methyl-2-quinazolinyl)guanidine.

15 Data: ESMS 232 (MH^+); 1H NMR (CD_3OD) δ 7.77 (d, $J = 9.0$ Hz, 1H), 7.54 (dd, $J = 9.3, 2.7$ Hz, 1H), 7.38 (d, $J = 2.7$ Hz, 1H), 3.94 (s, 3H), 2.87 (s, 3H).

Example 25

20

N-(7-isopropyl-4-methyl-2-quinazolinyl)guanidine is made in the same manner as *N*-(6,7-dibutoxy-4-methyl-2-quinazolinyl)guanidine (see Example 1) except that 3-isopropylaniline is used in place of 3,4-dibutoxyaniline.

Compound 1021 (class: Quinazolino-guanidine; synthesized using Method C (85%), except that reverse phase (C18) column chromatography eluting with acetonitrile was used in place of normal phase).

5 Name: *N*-(7-isopropyl-4-methyl-2-quinazolinyl)guanidine.

Data: ESMS 244 (MH⁺); ¹H NMR (CD₃OD) δ 8.11 (d, 1H, J = 8.4 Hz), 7.72 (d, 1H, J = 1.5 Hz), 7.54 (dd, 1H, J = 8.7, 1.8 Hz), 3.12 (septet, 1H, J = 6.9 Hz), 2.88 (s, 3H), 1.34 (d, 6H, J = 6.9 Hz).

10

Example 26

N-[4-methyl-6-(trifluoromethoxy)-2-quinazolinyl]guanidine is made in the same manner as *N*-(6,7-dibutoxy-4-methyl-2-quinazolinyl)guanidine (see Example 1) except that 4-trifluoromethoxyaniline is used in place of 3,4-dibutoxyaniline.

20 Name: 2,2,4-trimethyl-6-(trifluoromethoxy)-1,2-dihydroquinoline. (Synthesized using Method B (19% yield)).

Data: ESMS 258 (MH⁺); ¹H NMR (CDCl₃) δ 6.89 (br d, 1H, J = 1.8 Hz), 6.83 (br dd, 1H, J = 8.7, 1.5 Hz), 6.37 (d, 1H, J = 8.4 Hz), 5.37 (br s, 1H), 1.96 (d, 3H, J = 1.2 Hz), 1.28 (s, 6H).

Compound 1030 (synthesized using Method C (11% yield)).

Name: *N*-[4-methyl-6-(trifluoromethoxy)-2-quinazolinyl]guanidine.

Data: ESMS 286 (MH⁺); ¹H NMR (CD₃OD) δ 8.02 (br d, 1H, J = 2.1 Hz), 7.90 (d, 1H, J = 9.3 Hz), 7.77 (br dd, 1H, J = 8.7, 1.8 Hz), 2.88 (s, 3H).

Example 27

10 *N*-(4-methyl-6-pentyl-2-quinazolinyl)guanidine is made in the same manner as *N*-(6,7-dibutoxy-4-methyl-2-quinazolinyl)guanidine (see Example 1) except that 4-pentylaniline is used in place of 3,4-dibutoxyaniline.

15 Name: 2,2,4-trimethyl-6-pentyl-1,2-dihydroquinoline (synthesized using Method B (32 % yield)).

Data: ESMS 244 (MH⁺); ¹H NMR (CDCl₃) δ 6.86 (d, 1H, J = 0.9 Hz), 6.80 (dd, 1H, J = 7.8, 0.9 Hz), 6.37 (d, 1H, J = 7.8 Hz), 5.30 (br s, 1H), 2.47 (t, 2H, J = 7.5 Hz), 1.98 (d, 3H, J = 0.9 Hz), 1.54 (br p, 2H, J = 7.2 Hz), 1.34-1.25 (m, 4H), 1.26 (s, 6H), 0.88 (br t, 3H, J = 6.6 Hz).

Compound 2001

Name: *N*-(4-methyl-6-pentyl-2-quinazolinyl)guanidine

(synthesized using Method C (9-41% yield). crystallization from MeOH and reverse phase (C18) HPLC were required).

Data: ESMS 272 (MH⁺); ¹H NMR (CD₃OD) δ 7.97 (s, 1H, 2nd order coupling), 7.81 (br s, 2H, 2nd order coupling), 2.91 (s, 3H),
5 2.82 (t, 2H, J = 7.8 Hz), 1.73-1.68 (m, 2H), 1.38-1.34 (m, 4H), 0.90 (br t, 3H, J = 6.6 Hz).

Example 28

10 N-(4,6,7-trimethyl-2-quinazolinyl)guanidine is made in the same manner as N-(6,7-dibutoxy-4-methyl-2-quinazolinyl)guanidine (see Example 1) except that 3,4-dimethylaniline is used in place of 3,4-dibutoxyaniline.

15 Name: 2,2,4,6,7-pentamethyl-1,2-dihydroquinoline (synthesized using Method B (47% yield)).

Data: ¹H NMR (CDCl₃) δ 6.82 (s, 1H), 6.28 (s, 1H), 5.24 (d, 1H, J = 0.9 Hz), 2.14 (s, 6H), 1.96 (d, 3H, J = 1.2 Hz), 1.24 (s, 6H).

20

Compound 1015 (class: Quinazolino-guanidine; synthesized using Method C (12% yield)).

Name: N-(4,6,7-trimethyl-2-quinazolinyl)guanidine.

Data: ESMS 230 (MH⁺); ¹H NMR (CD₃OD) δ 7.93 (s, 1H), 7.66 (s,

1H), 2.87 (s, 3H), 2.48 (s, 3H), 2.47 (s, 3H).

Example 29

5 *N*-[6-(benzyloxy)-4-methyl-2-quinazolinyl]guanidine is made in the same manner as *N*-(6,7-dibutoxy-4-methyl-2-quinazolinyl)guanidine (see Example 1) except that 4-benzyloxyaniline is used in place of 3,4-dibutoxyaniline.

10 Name: 6-(benzyloxy)-2,2,4-trimethyl-1,2-dihydroquinoline (synthesized using Method B (60% yield)).

Data: ESMS 280 (MH⁺).

Compound 1028 (class: Quinazolino-guanidine; synthesized
15 using Method C (6% yield)).

Name: *N*-[6-(benzyloxy)-4-methyl-2-quinazolinyl]guanidine.

Data: ESMS 308 (MH⁺); ¹H NMR (CD₃OD) δ 7.83 (br d, 1H, J = 9.0 Hz), 7.66 (br d, 1H, J = 9.0 Hz), 7.55-7.48 (m, 3H), 7.40-4.31 (m, 4H), 5.25 (s, 2H), 2.87 (s, 3H).

20

Example 30

N-[7-(1-hydroxyethyl)-4-methyl-2-quinazolinyl]guanidine is

made in the same manner as *N*-(6,7-dibutoxy-4-methyl-2-quinazolinyl)guanidine (see Example 1) except that 3-(1-hydroxyethyl)aniline is used in place of 3,4-dibutoxyaniline.

5 Compound 1035

Name: *N*-[7-(1-hydroxyethyl)-4-methyl-2-quinazolinyl]guanidine
(synthesized using Method C (86% yield)).

Data: ESMS 246 (MH⁺); ¹H NMR (CD₃OD) δ 8.17 (d, 1H, J = 8.7 Hz), 7.87 (s, 1H), 7.64 (d, 1H, J = 8.7 Hz), 5.02 (q, 1H, J =
10 6.6 Hz), 2.91 (br s, 3H), 1.50 (d, 3H, J = 6.6 Hz).

Example 31

N-(6-ethyl-4-methyl-2-quinazolinyl)guanidine is made in the
15 same manner as *N*-(6,7-dibutoxy-4-methyl-2-quinazolinyl)guanidine (see Example 1) except that 4-ethylaniline is used in place of 3,4-dibutoxyaniline.

Name: 6-ethyl-2,2,4-trimethyl-1,2-dihydroquinoline
20 (synthesized using Method B (38% yield)).

Data: ESMS 202 (MH⁺); ¹H NMR (CDCl₃) δ 6.89 (d, 1H, J = 1.5 Hz), 6.83 (dd, 1H, J = 8.1, 1.8 Hz), 6.39 (d, 1H, J = 8.1 Hz), 5.31 (d, 1H, J = 0.9 Hz), 2.52 (q, 2H, J = 7.5 Hz), 1.99 (d, 3H, J = 1.2 Hz), 1.26 (s, 6H), 1.19 (t, 3H, J = 7.5 Hz).

88

Compound 1003 (class: Quinazolino-guanidine; synthesized using Method C (7% yield)).

Name: *N*-(6-ethyl-4-methyl-2-quinazolinyl)guanidine.

5 Data: ESMS 230 (MH⁺); ¹H NMR (CD₃OD) δ 7.97 (br s, 1H, 2nd order coupling), 7.818 (s, 1H, 2nd order coupling), 7.815 (s, 1H, 2nd order coupling), 2.91 (s, 3H), 2.85 (q, 2H, J = 7.5 Hz), 1.32 (t, 3H, J = 7.5 Hz).

Example 32

10

N-(6-sec-butyl-4-methyl-2-quinazolinyl)guanidine is made in the same manner as *N*-(6,7-dibutoxy-4-methyl-2-quinazolinyl)guanidine (see Example 1) except that 4-sec-butylaniline is used in place of 3,4-dibutoxyaniline.

15

Name: 6-sec-butyl-2,2,4-trimethyl-1,2-dihydroquinoline (synthesized using Method B (50% yield)).

20 Data: ESMS 230 (MH⁺); ¹H NMR (CDCl₃) δ 6.86 (br s, 1H), 6.80 (br d, 1H, J = 8.7 Hz), 6.39 (br d, 1H, J = 8.5 Hz), 5.30 (br s, 1H), 2.50-2.40 (m, 1H), 1.99 (s, 3H), 1.53 (q, 2H, J = 7.2 Hz), 1.27 (s, 6H), 1.19 (d, 3H, J = 6.9 Hz), 0.82 (t, 3H, J = 7.5 Hz).

Compound 2002 (class: Quinazolino-guanidine; synthesized

using Method C (36% yield)).

Name: *N*-(6-*sec*-butyl-4-methyl-2-quinazolinyl)guanidine.

Data: ESMS 258 (MH⁺); ¹H NMR (CD₃OD) δ 7.90 (s, 1H, 2nd order coupling), 7.787 (s, 1H, 2nd order coupling), 7.791 (s, 1H, 2nd order coupling), 2.88 (s, 3H), 2.83 (septet, 1H, J = 7.2 Hz), 1.69 (p, 2H, J = 7.2 Hz), 1.31 (d, 3H, J = 6.9 Hz), 0.83 (t, 3H, J = 7.2 Hz).

Example 33

10

N-(4-methylfuro[2,3-*g*]quinazolin-2-yl)guanidine is made in the same manner as *N*-(6,7-dibutoxy-4-methyl-2-quinazolinyl)guanidine (see Example 1) except that 5-nitro-[2,3]-benzofuran is used in place of 1,2-dibutoxy-4-nitrobenzene.

15

Name: 6,6,8-trimethyl-5,6-dihydrofuro[2,3-*g*]quinoline (synthesized using Method B (70% yield)).

20 Data: ¹H NMR (CDCl₃) δ 7.53 (br s, 1H), 7.21 (dd, 1H, J = 8.4, 0.6 Hz), 6.94 (br s, 1H), 6.51 (d, 1H, J = 8.4 Hz), 5.38 (d, 1H, J = 1.2 Hz), 2.29 (d, 3H, J = 1.2 Hz), 1.29 (s, 6H).

Compound 1039

Name: *N*-(4-methylfuro[2,3-*g*]quinazolin-2-yl)guanidine (class: Quinazolino-guanidine; synthesized using Method C (85% yield)).

Data: ESMS 242 (MH⁺); ¹H NMR (CD₃OD) δ 8.18 (d, 1H, J = 9.6 Hz), 8.14 (br s, 1H,), 7.85 (d, 1H, J = 9.0 Hz), 7.53 (br s, 1H), 3.13 (s, 3H).

Example 34

10 *N*-(6-butoxy-4-methyl-2-quinazolinyl)guanidine is made in the same manner as *N*-(6,7-dibutoxy-4-methyl-2-quinazolinyl)guanidine (see Example 1) except that 4-butoxyaniline is used in place of 3,4-dibutoxyaniline.

15 Name: butyl 2,2,4-trimethyl-1,2-dihydro-6-quinolinyl ether.
(synthesized using Method B (14% yield)).

Data: ESMS 246 (MH⁺); ¹H NMR (CDCl₃) δ 6.69 (br d, 1H, J = 2.7 Hz), 6.60 (dd, 1H, J = 8.4, 2.7 Hz), 6.40 (d, 1H, J = 8.4 Hz),
20 5.36 (br s, 1H), 3.89 (t, 2H, J = 6.6 Hz), 1.97 (d, 3H, J = 0.9 Hz), 1.72 (p, 2H, J = 5.7 Hz), 1.47 (septet, 2H, J = 7.2 Hz), 1.25 (s, 6H), 0.96 (t, 3H, J = 7.2 Hz).

Compound 1012 (class: Quinazolino-guanidine; synthesized

using Method C (12% yield)).

Name: N-(6-butoxy-4-methyl-2-quinazolinyl)guanidine.

Data: ESMS 247 (MH⁺); ¹H NMR (CD₃OD) δ 7.81 (d, 1H, J = 9.0 Hz), 7.56 (dm, 1H, J = 9.3 Hz), 7.50-7.40 (m, 1H), 4.14 (t, 2H, J = 6.0 Hz), 2.89 (s, 3H), 1.84 (p, 2H, J = 7.8 Hz), 1.55 (septet, 2H, J = 7.5 Hz), 1.01 (t, 3H, J = 7.5 Hz).

Example 35

10 N-(4-methyl-6-phenoxy-2-quinazolinyl)guanidine is made in the same manner as N-(6,7-dibutoxy-4-methyl-2-quinazolinyl)guanidine (see Example 1) except that 4-phenoxyaniline is used in place of 3,4-dibutoxyaniline.

15

Name: 2,2,4-trimethyl-6-phenoxy-1,2-dihydroquinoline (synthesized using Method B (10% yield)).

Data: ¹H NMR (CDCl₃) δ 7.187 (t, 2H, J = 7.8 Hz), 6.91 (t, 1H, J = 6.9 Hz), 6.81 (d, 2H, J = 7.8 Hz), 6.68 (d, 1H, J = 2.1 Hz), 6.60 (dd, 1H, J = 8.4, 2.1 Hz), 6.53 (d, 1H, J = 8.4 Hz), 5.37 (br s, 1H), 1.88 (d, 3H, J = 1.2 Hz), 1.23 (s, 6H).

Compound 1032 (class: Quinazolino-guanidine; synthesized using Method C (11% yield)).

Name: *N*-(4-methyl-6-phenoxy-2-quinazolinyl)guanidine.

Data: ESMS 294 (MH⁺); ¹H NMR (CD₃OD) δ 7.93 (d, 1H, J = 9.0 Hz), 7.66 (dd, 1H, J = 9.0, 2.7 Hz), 7.58 (d, 1H, J = 2.7 Hz), 7.42 (t, 2H, J = 7.5 Hz), 7.20 (t, 1H, J = 7.5 Hz), 7.09 (br d, 2H, J = 7.5 Hz), 2.79 (s, 3H).

Example 36

N-(6-cyclohexyl-4-methyl-2-quinazolinyl)guanidine is made in the same manner as *N*-(6,7-dibutoxy-4-methyl-2-quinazolinyl)guanidine (see Example 1) except that 4-cyclohexylaniline is used in place of 3,4-dibutoxyaniline.

Name: 6-cyclohexyl-2,2,4-trimethyl-1,2-dihydroquinoline.

(synthesized using Method B (47% yield)).

Data: ¹H NMR (CDCl₃) δ 7.00 (d, 1H, J = 1.8 Hz), 6.94 (dd, 1H, J = 8.1, 1.8 Hz), 6.45 (3, 1H, J = 8.1 Hz), 5.38 (d, 1H, J = 1.2 Hz), 2.55-2.42 (m 1H), 2.09 (s, 3H), 1.97-1.91 (m, 5H), 1.83 (br d, 1H, J = 12Hz), 1.55 - 1.42 (m, 4H), 1.34 (s, 6H).

Compound 1029 (class: Quinazolino-guanidine; synthesized using Method C (14% yield)).

Name: *N*-(6-cyclohexyl-4-methyl-2-quinazolinyl)guanidine.

Data: ESMS 284 (MH⁺).

Example 37

N-[4-methyl-6-(pentyloxy)-2-quinazolinyl]guanidine is made in the same manner as *N*-(6,7-dibutoxy-4-methyl-2-quinazolinyl)guanidine (see Example 1) except that 4-pentyloxyaniline is used in place of 3,4-dibutoxyaniline.

Name: Pentyl 2,2,4-trimethyl-1,2-dihydro-6-quinolinyl ether.
(synthesized using Method B (59% yield))

10

Data: ESMS 260 (MH⁺).

Compound 1031 (class: Quinazolino-guanidine; synthesized using Method C (13% yield)).

15 Name: *N*-[4-methyl-6-(pentyloxy)-2-quinazolinyl]guanidine.

Data: ESMS 288 (MH⁺); ¹H NMR (CD₃OD) δ 7.82 (d, 1H, J = 9.3 Hz), 7.57 (dd, 1H, J = 9.0, 2.4 Hz), 7.41 (d, 1H, J = 2.7 Hz), 4.13 (t, 2H, J = 6.3 Hz), 2.89 (s, 3H), 1.86 (br p, 2H, J = 7.2 Hz), 1.55-1.35 (m, 4H), 0.95 (br t, 3H, J = 7.2 Hz).

20

Example 38

N-[4-methyl-6-(4-methylphenoxy)-2-quinazolinyl]guanidine is

made in the same manner as *N*-(6,7-dibutoxy-4-methyl-2-quinazolinyl)guanidine (see Example 1) except that 4-(4-methylphenoxy)aniline is used in place of 3,4-dibutoxyaniline.

- 5 Name: 2,2,4-trimethyl-6-(4-methylphenoxy)-1,2-dihydroquinoline
(synthesized using Method B (27% yield)).

Data: ESMS 280 (MH⁺).

- Compound 1033 (class: Quinazolino-guanidine; synthesized
10 using Method C (9% yield)).

Name: *N*-[4-methyl-6-(4-methylphenoxy)-2-quinazolinyl]guanidine.

- Data: ESMS 308 (MH⁺); ¹H NMR (CD₃OD) δ 7.89 (d, 1H, J = 9.0
Hz), 7.86 (s, 1H), 7.62 (dd, 1H, J = 9.0, 2.7 Hz), 7.47 (d,
15 1H, J = 2.4 Hz), 7.23 (d, 2H, J = 8.1 Hz), 6.97 (d, 2H, J =
8.4 Hz), 2.75 (s, 3H), 2.34 (s, 3H).

Example 39

- 20 *N*-(6-tert-butyl-4-methyl-2-quinazolinyl)guanidine is made in
the same manner as *N*-(6,7-dibutoxy-4-methyl-2-quinazolinyl)guanidine (see Example 1) except that 6-tert-butylaniline is used in place of 3,4-dibutoxyaniline.

Name: 6-(tert-butyl)-2,2,4-trimethyl-1,2-dihydroquinoline.

(synthesized using method B (72% yield)).

Data: ESMS 230 (MH⁺); ¹H NMR (CDCl₃) δ 6.99 (d, J = 7.8 Hz, 1H), 6.66 (dd, J = 7.8, 1.5 Hz, 1H), 6.46 (d, J = 1.5 Hz, 1H),
5 5.25 (s, 1H), 3.68 (bs, 1H), 1.97 (d, J = 1.2 Hz, 3H), 1.28 (d, J = 6.0 Hz, 6H), 1.27 (s, 6H).

Compound 1004 (class: Quinazolino-guanidine; synthesized using Method C (45% yield)).

10 Name: N-(6-tert-butyl-4-methyl-2-quinazolinyl)guanidine.

Data: ESMS 258 (MH⁺); ¹H NMR (CD₃OD) δ 8.00-8.36 (m, 2H), 7.82 (d, J = 8.7 Hz, 1H), 2.90 (s, 3H), 1.42 (s, 9H); Anal. (C₁₄H₁₉N₅. 1.1 CHCl₃. 2.4 NH₃) calcd, C 42.22, H 6.40, N 24.13; Found, C 42.13, H 6.36, N 24.23.

15

Example 40

N-(7-ethoxy-4-methyl-2-quinazolinyl)guanidine is made in the same manner as N-(6,7-dibutoxy-4-methyl-2-quinazolinyl)guanidine (see Example 1) except that 3-ethoxyaniline is used in place of 3,4-dibutoxyaniline.

20

Name: 7-ethoxy-2,2,4-trimethyl-1,2-dihydroquinoline.

(synthesized using Method B (37% yield)).

Data: ¹H NMR (CDCl₃) δ 6.97 (d, J = 8.4 Hz, 1H), 6.20 (dd, J = 8.4, 2.4 Hz, 1H), 6.02 (d, J = 2.4 Hz, 1H), 5.19 (d, J = 1.3 Hz, 1H), 3.98 (q, J = 7.0 Hz, 2H), 3.53 (bs, 1H), 1.97 (d, J = 1.4 Hz, 3H), 1.39 (t, J = 7.0 Hz, 3H), 1.27 (s, 6H).

Compound 1024 (class: Quinazolino-guanidine; synthesized using Method C (42% yield)).

Name: N-(7-ethoxy-4-methyl-2-quinazolinyl)guanidine.

10 Data: ESMS 244 (MH⁺); ¹H NMR (CD₃OD) δ 8.06 (d, J = 9.1 Hz, 1H), 7.44 (d, J = 2.4 Hz, 1H), 7.31 (dd, J = 9.1, 2.5 Hz, 1H), 4.21 (q, J = 7.0 Hz, 2H), 2.83 (s, 3H), 1.46 (t, J = 7.0 Hz, 3H); Anal. (C₁₂H₁₅N₅O · 1.28 CF₃CO₂H) calcd, C 44.70; H 4.19, N 17.90; Found, C 44.80, H 4.09, N 17.80.

15

Example 41

N-[7-(tert-butyl)-4-methyl-2-quinazolinyl]guanidine is made in the same manner as N-(6,7-dibutoxy-4-methyl-2-quinazolinyl)guanidine (see Example 1) except that 3-tert-butylaniline is used in place of 3,4-dibutoxyaniline.

Name: 7-(tert-butyl)-2,2,4-trimethyl-1,2-dihydroquinoline.

(synthesized using Method B (82% yield)).

Data: ^1H NMR (CDCl_3) δ 6.99 (d, J = 7.8 Hz, 1H), 6.66 (dd, J = 7.8, 1.5 Hz, 1H), 6.46 (d, J = 1.5 Hz, 1H), 5.25 (s, 1H), 3.68 (bs, 1H), 1.97 (d, J = 1.2 Hz, 3H), 1.28 (d, J = 6.0 Hz, 6H), 1.27 (s, 6H).

5

Compound 1022 (class: Quinzolino-guanidine; synthesized using Method C (44% yield)).

Name: *N*-[7-(tert-butyl)-4-methyl-2-quinazolinyl]guanidine.

10 Data: ESMS 258 (MH^+); ^1H NMR (CD_3OD) δ 8.09 (d, J = 8.7 Hz, 1H), 7.84 (d, J = 1.8 Hz, 1H), 7.72 (dd, J = 8.7, 1.8 Hz, 1H), 2.86 (s, 3H), 1.41 (s, 9H); mp 195 - 198 °C (dec.); Anal. ($\text{C}_{14}\text{H}_{19}\text{N}_5$ · 0.9 CH_2Cl_2 · 1.2 H_2O · 0.9 NH_3) calcd, C 48.27, H 7.04, N 22.29; Found, C 47.99, H 7.04, N 22.26.

15 Example 42

N-(6-hydroxy-4,7-dimethyl-2-quinazolinyl)guanidine is made in the same manner as *N*-(6,7-dibutoxy-4-methyl-2-quinazolinyl)guanidine (see Example 1) except that 6-nitro-3,4-dihydro-1(2*H*)-naphthalenone is used in place of 1,2-dibutoxy-4-nitrobenzene.

20

Name: 6-amino-1,2,3,4-tetrahydro-1-naphthalenol.

(synthesized from 6-nitro-3,4-dihydro-1(2*H*)-naphthalenone

using Method A (67% yield).

Data: ESMS 164 (MH⁺); ¹H NMR (CDCl₃) δ 6.90 (d, 1H, J = 8.1 Hz), 6.79 (d, 1H, J = 2.4 Hz), 6.58 (dd, 1H, J = 8.1, 2.4 Hz), 4.68 (t, 1H, J = 5.4 Hz), 2.68-2.60 (m, 2H), 2.00-1.71 (m, 4H).

Compound 1017 (class: Quinazolino-guanidine; synthesized using methods B & C (28% yield over 2 steps)).

Name: N-(6-hydroxy-4,7-dimethyl-2-quinazolinyl)guanidine.

10 Data (CF₃CO₂H salt): ESMS 232 (MH⁺); ¹H NMR (CD₃OD) δ 7.63 (s, 1H), 7.28 (s, 1H), 2.80 (s, 3H), 2.4 (s, 3H); mp 246 - 248 °C (dec.); Anal. (C₁₁H₁₃N₅O. 1.25 CF₃CO₂H. 1 H₂O) calcd, C 41.39, H 4.18, N 17.87; Found, C 41.52, H 4.14, N 17.95.

15 Example 43

N-(6-methoxy-4,7-dimethyl-2-quinazolinyl)guanidine is made in the same manner as N-(6,7-dibutoxy-4-methyl-2-quinazolinyl)guanidine (see Example 1) except that 4-methoxyaniline is used in place of 3,4-dibutoxyaniline.

Name: 6-methoxy-2,2,4,7-tetramethyl-1,2-dihydroquinoline.

(Synthesized using Method B (82% yield)).

Data: ESMS 218 (MH⁺).

Compound 1016 (class: Quinazolino-guanidine; synthesized using Method C (41% yield)).

Name: *N*-(6-methoxy-4,7-dimethyl-2-quinazolinyl)guanidine.

Data: ESMS 244 (MH⁺); ¹H NMR (CD₃OD) δ 7.63 (s, 1H), 7.30 (s, 1H), 3.98 (s, 3H), 2.86 (s, 3H), 2.39 (s, 3H).

Example 44

N-(4-methyl-8,9-dihydrobenzo[*g*]quinazolin-2-yl)guanidine is made in the same manner as *N*-(6,7-dibutoxy-4-methyl-2-quinazolinyl)guanidine (see Example 1) except that 7-nitro-1-tetralone is used in place of 1,2-dibutoxy-4-nitrobenzene.

Compound 1037 (class: Quinazolino-guanidine; synthesized using Method C (11% yield)).

Name: *N*-(4-methyl-8,9-dihydrobenzo[*g*]quinazolin-2-yl)guanidine.

Data: ESMS 254 (MH⁺); ¹H NMR (CD₃OD) δ 7.89 (s, 2H), 7.77 (s, 1H), 7.36 (s, 1H), 6.66 (d, 1H, *J* = 9.6 Hz), 6.36 (dt, 1H, *J* = 9.3, 4.5 Hz), 2.97 (br t, 2H, *J* = 7.5 Hz), 2.80 (br s, 3H), 2.45-2.37 (m, 2H).

Example 45

100

N-(4-methyl-7,8-dihydro-6*H*-cyclopenta[*g*]quinazolin-2-yl)guanidine is made in the same manner as *N*-(6,7-dibutoxy-4-methyl-2-quinazolinyl)guanidine (see Example 1) except that 5-aminoindane is used in place of 3,4-dibutoxyaniline.

5

Name: 2,2,4-trimethyl-2,6,7,8-tetrahydro-1*H*-cyclopenta[*g*]quinoline (synthesized using Method B (93% yield)).

Data: ESMS 214 (MH⁺); ¹H NMR (CDCl₃) δ 6.96 (s, 1H), 6.38 (s, 1H), 5.28 (d, 1H, J = 0.6 Hz), 2.80 (t, 4H, J = 7.2 Hz), 2.16 (br t, 1H, J = 7.5 Hz), 2.03 (br t, 1H), 1.99 (br d, 3H, J = 0.9 Hz), 1.27 (s, 6H).

Compound 1038 (class: Quinazolino-guanidine; synthesized using Method C (18% yield)).

15 Name: *N*-(4-methyl-7,8-dihydro-6*H*-cyclopenta[*g*]quinazolin-2-yl)guanidine.

Data: ESMS 242 (MH⁺); ¹H NMR (CD₃OD) δ 7.96 (s, 1H), 7.66 (s, 1H), 3.09 (dd, 4H, J = 6.9, 6.0 Hz), 2.86 (s, 3H), 2.20 (p, 2H, J = 7.5 Hz); mp 295 - 298 °C (dec.).

20

Example 46

N-4-methyl-6-[(5-phenoxypropyl)oxy]-2-quinazolinylguanidine is made in the same manner as *N*-(6,7-dibutoxy-4-methyl-2-

101

quinazolinyl)guanidine (see Example 1) except that 4-[(5-phenoxypropyl)oxy]aniline is used in place of 3,4-dibutoxyaniline.

- 5 Name: 2,2,4-trimethyl-6-[(5-phenoxypropyl)oxy]-1,2-dihydroquinoline (synthesized using Method B).

Data: 352 (ESMS, MH⁺).

- 10 Compound 1005 (class: Quinazolino-guanidine; synthesized using Method C (12% yield)).

Name: N-4-methyl-6-[(5-phenoxypropyl)oxy]-2-quinazolinylguanidine.

- 15 Data: ESMS 379 (MH⁺); ¹H NMR (CD₃OD) δ 7.79 (d, J = 9.2 Hz, 1H), 7.54 (dd, J = 9.2, 2.6 Hz, 1H), 7.38 (d, J = 2.5 Hz, 1H), 7.21 (t, J = 8.0 Hz, 2H), 6.82-6.90 (m, 3H), 4.15 (t, J = 6.2 Hz, 2H), 3.98 (t, J = 6.2 Hz, 2H), 2.86 (3H, s), 1.62-2.00 (m, 6H).

Example 47

20

N-(6-butyl-4-methyl-2-quinazolinyl)guanidine is made in the same manner as N-(6,7-dibutoxy-4-methyl-2-quinazolinyl)guanidine (see Example 1) except that 4-butylaniline is used in place of 3,4-dibutoxyaniline.

102

Name: 6-butyl-2,2,4-trimethyl-1,2-dihydroquinoline.

(synthesized using Method B (14% yield)).

Data: ESMS 230 (MH⁺); ¹H NMR (CDCl₃) δ 6.93 (s, 1H), 6.86 (d, 1H, J = 8.1 Hz), 6.42 (d, 1H, J = 7.8 Hz), 5.35 (br s, 1H),
5 2.54 (t, 2H, J = 7.5 Hz), 2.04 (s, 3H), 1.60 (p, 2H, J = 7.5 Hz), 1.40 (septet, 2H, J = 7.2 Hz), 1.304 (s, 3H), 1.301 (s, 3H), 0.97 (t, 3H, J = 7.2 Hz).

Compound 2004 (class: Quinazolino-guanidine; synthesized
10 using Method C (44% yield)).

Name: N-(6-butyl-4-methyl-2-quinazolinyl)guanidine.

Data: ESMS 258 (MH⁺); ¹H NMR (CD₃OD) δ 7.92 (s, 1H, 2nd order coupling), 7.77 (s, 2H, 2nd order coupling), 2.88 (s, 3H), 2.80 (t, 2H, J = 7.5 Hz), 1.67 (p, 2H, J = 7.8 Hz), 1.39 (septet, 2H, J = 7.5 Hz), 0.95 (t, 3H, J = 7.2 Hz).
15

Example 48

N-(6-benzyl-4-methyl-2-quinazolinyl)guanidine is made in the
20 same manner as N-(6,7-dibutoxy-4-methyl-2-quinazolinyl)guanidine (see Example 1) except that 4-benzylaniline is used in place of 3,4-dibutoxyaniline.

Name: 6-benzyl-2,2,4-trimethyl-1,2-dihydroquinoline.

(synthesized using Method B (41% yield)).

Data: ESMS 263 (MH⁺); ¹H NMR (CDCl₃) δ 7.14 (t, 2H, J = 7.5 Hz), 7.35-7.33 (m, 3H), 7.07 (s, 1H), 6.95 (d, 1H, J = 7.8 Hz), 6.51 (dd, 1H, J = 8.1, 0.9 Hz), 5.45 (br s, 1H), 4.02 (s, 2H), 2.11 (s, 3H), 1.399 (s, 3H), 1.395 (s, 3H).

Compound 2003 (class: Quinazolino-guanidine; synthesized using Method C (19% yield)).

Name: N-(6-benzyl-4-methyl-2-quinazolinyl)guanidine.

10 Data: ESMS 298 (MH⁺); ¹H NMR (DMSO-d₆) δ 7.62 (br s, 1H), 7.44 (d, 1H, J = 8.4 Hz), 7.33 (d, 1H, J = 8.1 Hz), 7.22-7.06 (m, 5H), 3.93 (s, 2H), 2.56 (s, 3H).

Example 49

15

N-(6-hexyl-4-methyl-2-quinazolinyl)guanidine is made in the same manner as N-(6,7-dibutoxy-4-methyl-2-quinazolinyl)guanidine (see Example 1) except that 4-hexylaniline is used in place of 3,4-dibutoxyaniline.

20

Name: 6-hexyl-2,2,4-trimethyl-1,2-dihydroquinoline.

(synthesized using Method B (32% yield)).

Data: ESMS 258 (MH⁺); ¹H NMR (CDCl₃) δ 7.12 (s, 1H), 7.08 (d, 7.8 Hz), 6.55 (dd, 1H, J = 7.8, 1.2 Hz), 5.50 (d, 1H, J = 1.2

Hz), 2.73 (t, 2H, J = 7.2 Hz), 2.21 (d, 3H, J = 1.2 Hz), 1.82 (br t, 2H, J = 6.0 Hz), 1.55 (br s, 6H), 1.45 (s, 3H), 1.44 (s, 3H), 1.14 (br s, 3H).

- 5 Compound 2005 (class: Quinazolino-guanidine; synthesized using Method C (5 % yield)).

Name: N-(6-hexyl-4-methyl-2-quinazolinyl)guanidine.

- Data: ESMS 286 (MH⁺); ¹H NMR (CD₃OD) δ 7.88 (s, 1H), 7.86 (s, 1H, 2nd order coupling), 7.73 (br s, 2H, 2nd order coupling),
10 2.84 (s, 3H), 2.77 (t, 2H, J = 7.8 Hz), 1.6 (br s, 2H), 1.40-1.25 (m, 6H), 0.87 (br t, 3H, J = 6.9 Hz).

Example 50

- 15 N-[7-(benzyloxy)-4-methyl-2-quinazolinyl]guanidine is made in the same manner as N-(6,7-dibutoxy-4-methyl-2-quinazolinyl)guanidine (see Example 1) except that 3-(benzyloxy)aniline is used in place of 3,4-dibutoxyaniline.

- 20 Name: 7-(benzyloxy)-2,2,4-trimethyl-1,2-dihydroquinoline.
(synthesized using Method B (72% yield)).

Data: ¹H NMR (CDCl₃) δ 7.34-7.52 (m, 5H), 7.04 (d, J = 8.4 Hz, 1H), 6.34 (dd, J = 8.4, 2.4 Hz, 1H), 6.16 (d, J = 2.4 Hz, 1H), 5.26 (d, J = 0.9 Hz, 1H), 5.06 (s, 2H), 3.62 (bs, 1H),

2.02 (d, J = 0.9 Hz, 3H), 1.32 (s, 6H).

Compound 1006 (class: Quinazolino-guanidine; synthesized using method C (43% yield)).

5 Name: N-[7-(benzyloxy)-4-methyl-2-quinazolinyl]guanidine.

Data: ESMS 308 (MS⁺); ¹H NMR (CD₃OD) δ 8.01 (d, J = 9.0 Hz, 1H), 7.17-7.48 (m, 6H), 7.20 (dd, J = 9.0, 2.4 Hz, 1H), 5.20 (s, 2H), 2.78 (s, 3H); mp 215 - 217 °C (dec.); Anal. (C₁₇H₁₇N₅O.CF₃CO₂H. 0.2 CH₂Cl₂) calcd, C 52.61, H 4.23, N 15.98;
10 Found, C 52.63, H 4.26, N 16.02.

Example 51

N-(6-heptyl-4-methyl-2-quinazolinyl)guanidine is made in the
15 same manner as N-(6,7-dibutoxy-4-methyl-2-quinazolinyl)guanidine (see Example 1) except that 4-heptylaniline is used in place of 3,4-dibutoxyaniline.

Name: 6-heptyl-2,2,4-trimethyl-1,2-dihydroquinoline.
20 (synthesized using Method B (50% yield)).

Data: ESMS 272 (MH⁺); ¹H NMR (CDCl₃) δ 6.89 (dd, 1H, J = 1.5 Hz), 6.82 (dd, 1H, J = 8.1, 2.1 Hz), 5.32 (br s, 1H), 2.49 (br t, 2H, J = 7.5 Hz), 2.01 (d, 3H, J = 1.2 Hz), 1.60-1.53 (m, 2H), 1.32-1.30 (m, 8H), 1.27 (s, 6H), 0.90 (t, 3H, J = 6.9

Hz).

Compound 2006 (class: Quinazolino-guanidine; synthesized using Method C (18% yield)).

5 Name: *N*-(6-heptyl-4-methyl-2-quinazolinyl)guanidine.

Data: ESMS 300 (MH⁺); ¹H NMR (DMSO-d₆) δ 7.87 (s, 1H), 7.67 (br s, 2H, 2nd order coupling), 2.79 (s, 3H), 2.72 (t, 2H), 1.63 (br s, 2H), 1.30 (br s, 4H), 1.24 (br s, 4H), 0.84 (br t, 3H, J = 6.3 Hz).

10

Example 52

N-(4-methyl-6-pentyl-2-quinoliny)guanidine is made in the same manner as *N*-(6-ethyl-4-methyl-2-quinoliny)guanidine (see
15 Example 3) except that 4-pentylaniline is used in place of 4-ethylaniline.

Name: 3-oxo-*N*-(4-pentylphenyl)butanamide.

(synthesized from 4-pentylaniline using Method G (28-36%
20 yield)).

Data: ESMS 246 (MH⁺); ¹H NMR (CDCl₃) δ 9.05 (br s, 1H), 7.43 (d, 2H, J = 8.4 Hz), 7.13 (d, 2H, J = 8.4 Hz), 3.58 (s, 2H), 2.56 (t, 2H, J = 7.5 Hz), 2.32 (s, 3H), 1.58 (p, 2H, J = 7.2 Hz), 1.35-1.26 (m, 4H), 0.88 (t, 3H, J = 6.9 Hz).

Name: 4-methyl-6-pentyl-2(1H)-quinolinone.

(synthesized using Method H (76-96% yield)).

5 Data: ESMS 230 (MH⁺); ¹H NMR (CDCl₃) δ 11.92 (br s, 1H), 7.45 (s, 1H, 2nd order coupling), 7.33 (br s, 2H, 2nd order coupling), 6.57 (s, 1H), 2.68 (t, 2H, J = 7.8 Hz), 2.51 (s, 3H), 1.64 (br s, 2H), 1.36 (br s, 4H), 0.90 (br s, 3H).

Name: 2-chloro-4-methyl-6-pentylquinoline.

(synthesized using Method I (33% yield)).

10 Data: ESMS 250 & 248 (MH⁺); ¹H NMR (CD₃OD) δ 7.83 (br s, 1H), 7.81 (d, 1H, J = 8.7 Hz), 7.63 (dd, 1H, J = 8.7, 2.1 Hz), 7.33 (d, 1H, J = 0.9 Hz), 2.81 (t, 2H, J = 7.8 Hz), 2.69 (d, 3H, J = 0.9 Hz), 1.71 (br p, 2H, J = 7.8 Hz), 1.38-1.33 (m, 4H), 0.90 (br t, 3H, J = 6.9 Hz).

15

Compound 5002 (class: Quinolino-guanidine; synthesized using Method J (2% yield)).

Name: N-(4-methyl-6-pentyl-2-quinolinyl)guanidine.

20 Data: ESMS 271 (MH⁺); ¹H NMR (CD₃OD) δ 7.80 (d, 1H, J = 8.4 Hz), 7.75 (d, 1H, J = 1.2 Hz), 7.56 (dd, 1H, J = 8.4, 1.8 Hz), 6.98 (br s, 1H), 2.78 (dd, 2H, J = 7.8, 6.6 Hz), 2.66 (d, 3H, J = 0.6 Hz), 1.69 (br p, 2H, J = 7.8 Hz), 1.37-1.32 (m, 4H), 0.89 (br t, 3H, J = 6.6 Hz).

Example 53

N-(4-methyl-6-propyl-2-quinazolinyl)guanidine is made in the same manner as *N*-(6,7-dibutoxy-4-methyl-2-quinazolinyl)guanidine (see Example 1) except that 4-propylaniline is used in place of 3,4-dibutoxyaniline.

Name: 2,2,4-trimethyl-6-propyl-1,2-dihydroquinoline.

(synthesized using Method B (89% yield)).

10 Data: ESMS 216 (MH⁺); ¹H NMR (CDCl₃) δ 6.91 (d, 1H, J = 1.8 Hz), 6.84 (dd, 1H, J = 7.8, 1.8 Hz), 6.41 (d, 1H, J = 7.8 Hz), 5.34 (d, 1H, J = 1.2 Hz), 2.50 (t, 2H, J = 7.5 Hz), 2.02 (d, 3H, J = 1.2 Hz), 1.62 (septet, 2H, J = 7.8 Hz), 1.29 (s, 6H), 0.96 (t, 3H, J = 7.5 Hz).

15

Compound 1008 (synthesized using Method C (24% yield)).

Name: *N*-(4-methyl-6-propyl-2-quinazolinyl)guanidine.

Data: ESMS 244 (MH⁺); ¹H NMR (CDCl₃) δ 7.64 (s, 1H, 2nd order coupling), 7.58 (s, 2H, 2nd order coupling), 2.80 (s, 3H), 2.68 (t, 2H, J = 7.2 Hz), 1.65 (septet, 2H, J = 7.5 Hz), 0.93 (t, 3H, J = 8.4 Hz).

20

Example 54

N-(4-methyl-6-phenyl-2-quinazolinyl)guanidine is made in the same manner as *N*-(6,7-dibutoxy-4-methyl-2-quinazolinyl)guanidine (see Example 1) except that 4-phenylaniline is used in place of 3,4-dibutoxyaniline.

5

Name: 2,2,4-trimethyl-6-phenyl-1,2-dihydroquinoline.

(synthesized using Method B (61% yield)).

Data: ESMS 250 (MH⁺); ¹H NMR (CDCl₃) δ 7.77-7.72 (m, 2H), 7.60-7.50 (m, 3H), 7.47-7.40 (m, 2H), 6.65-6.50 (m, 1H), 5.51 (br s, 1H), 2.23 (br s, 3H), 1.44 (br s, 6H).

10

Compound 1010 (class: Quinazolino-guanidine; synthesized using Method C (3% yield)).

Name: *N*-(4-methyl-6-phenyl-2-quinazolinyl)guanidine.

15 Data: ESMS 278 (MH⁺); ¹H NMR (CD₃OD) δ 8.31 (d, 1H, J = 1.8 Hz), 8.19 (dd, 1H, 8.7, 1.8 Hz), 7.94 (d, 1H, J = 8.7 Hz), 7.75 (d, 2H, J = 7.2 Hz), 7.50 (t, 2H, J = 6.9 Hz), 7.40 (t, 1H, J = 7.2 Hz), 2.97 (s, 3H).

20 Example 55

N-(4-methyl-6-octyl-2-quinazolinyl)guanidine is made in the same manner as *N*-(6,7-dibutoxy-4-methyl-2-quinazolinyl)guanidine (see Example 1) except that 4-

octylaniline is used in place of 3,4-dibutoxyaniline.

Name: 2,2,4-trimethyl-6-octyl-1,2-dihydroquinoline.

(synthesized using Method B (72% yield)).

5 Data: ESMS 286 (MH⁺); ¹H NMR (CDCl₃) δ 6.90-6.75(m, 2H), 6.41-6.33 (m, 1H), 5.29 (br s, 1H), 2.50-2.42 (m, 2H), 2.01-1.96 (m, 3H), 1.55 (br s, 2H), 1.29-1.21 (m, 16H), 0.91-0.54 (m, 3H).

10 Compound 1009 (class: Quinazolino-guanidine; synthesized using Method C (12% yield)).

Name: N-(4-methyl-6-octyl-2-quinazolinyl)guanidine.

Data: ESMS 314 (MH⁺); ¹H NMR (DMSO-d₆) δ 7.79 (s, 1H, 2nd order coupling), 7.62-7.50 (m, 2H, 2nd order coupling), 2.732 (br s, 5H), 1.60 (br s, 2H), 1.21 (br s, 10H), 0.82 (br t, 3H).

15

Example 56

N-(6-hexyl-4-methyl-2-quinolinyl)guanidine is made in the same
20 manner as N-(6-ethyl-4-methyl-2-quinolinyl)guanidine (see Example 3) except that 4-hexylaniline is used in place of 4-ethylaniline.

111

Name: *N*-(4-hexylphenyl)-3-oxobutanamide.

(synthesized from 4-hexylaniline using Method G (54% yield)).

Name: 6-hexyl-4-methyl-2(1*H*)-quinolinone.

5 (synthesized using Method H (100% yield)).

Data: ESMS 244 (MH⁺).

Name: 2-chloro-6-hexyl-4-methylquinoline.

(synthesized using Method I (60% yield)).

10 Data: ESMS 264 & 262 (MH⁺); ¹H NMR (CDCl₃) δ 7.78 (br d, 1H, J = 2.4 Hz), 7.75 (s, 1H), 7.59 (dd, 1H, J = 8.7, 1.5 Hz), 7.27 (br s, 1H), 2.77 (t, 2H, J = 7.5 Hz), 2.64 (s, 3H), 1.67 (br p, 2H, J = 7.2 Hz), 1.31 (br s, 6H), 0.86 (br t, 3H, J = 6.9 Hz).

15

Compound 5003 (class: Quinolono-guanidine; synthesized using Method J (10% yield)).

Name: *N*-(6-hexyl-4-methyl-2-quinolinyl)guanidine.

20 Data: ESMS 285 (MH⁺); ¹H NMR (CD₃OD) δ 7.72 (d, 1H, J = 8.7 Hz), 7.67 (d, 1H, J = 0.9 Hz), 7.51 (dd, 1H, J = 8.4, 1.8 Hz), 6.92 (br s, 1H), 2.75 (t, 2H, J = 7.5 Hz), 2.60 (s, 3H), 1.67 (br p, 2H, J = 7.8 Hz), 1.32 (br s, 6H), 0.88 (br t, 3H, J = 6.9 Hz).

Example 57

N-(6-[1-(4-hydroxyl-pentyl)]-4-methyl-2-quinazolino)guanidine is made in the same manner as *N*-(6-ethyl-4-methyl-2-quinazolino)guanidine (see Example 1) except that 5-(4-aminophenyl)-2-pentanol is used in place of 4-ethylaniline.

Compound 1034

Name: *N*-(6-[1-(4-hydroxyl-pentyl)]-4-methyl-2-quinazolino)guanidine.

Data: ESMS 288 (MH⁺); ¹H NMR (CD₃OD) δ 7.96 (s, 1H), 7.80 (s, 2H), 3.74 (p, J = 6.3 Hz, 1H), 2.90 (s, 3H), 2.85-2.81 (m, 2H), 1.85-1.65 (m, 2H), 1.55-1.45 (m, 2H), 1.14 (d, J = 6.3 Hz, 3H).

Example 58

N-(6-butyl-4-methyl-2-quinolinyl)guanidine is made in the same manner as *N*-(6-ethyl-4-methyl-2-quinolinyl)guanidine (see Example 3) except that 4-butylaniline is used in place of 4-ethylaniline.

Compound 5001

Name: *N*-(6-butyl-4-methyl-2-quinolinyl)guanidine.

113

Data: ESMS 257 (MH⁺); ¹H NMR (CD₃OD) δ 7.82 (d, J = 8.4 Hz, 1H), 7.78 (d, J = 1.5 Hz, 1H), 7.58 (dd, J = 8.4, 1.5 Hz, 1H), 6.93 (s, 1H), 2.81 (t, J = 7.2 Hz, 2H), 2.68 (s, 3H), 1.69 (p, J = 7.2 Hz, 2H), 1.39 (sextet, J = 7.2 Hz, 2H), 0.95 (t, J = 7.2 Hz, 3H).

Example 59

N-(4-methyl-7-phenyl-2-quinazolinyl)guanidine is made in the same manner as *N*-(6,7-dibutoxy-4-methyl-2-quinazolinyl)guanidine (see Example 1) except that 3-phenylaniline is used in place of 3,4-dibutoxyaniline.

Compound 1023

Name: *N*-(4-methyl-7-phenyl-2-quinazolinyl)guanidine.

Data: ESMS 278 (MH⁺); ¹H NMR (CD₃OD) δ 8.17 (br s, 1H), 8.05 (br s, 1H), 7.84 (br s, 1H), 7.70 (br s, 2H), 7.43 (br s, 2H), 7.35 (br s, 1H), 2.87 (s, 3H).

Example 60

N-[4-methyl-7-(isopropoxy)-2-quinazolinyl]guanidine is made in the same manner as *N*-(6,7-dibutoxy-4-methyl-2-quinazolinyl)guanidine (see Example 1) except that 3-

114

isopropoxyaniline is used in place of 3,4-dibutoxyaniline.

Compound 1025

Name: *N*-[4-methyl-7-(isopropoxy)-2-quinazolinyl]guanidine.


5 Data: ESMS 260 (MH⁺); ¹H NMR (CD₃OD) ? 8.03 (d, J = 9.3 Hz, 1H), 7.23 (d, J = 2.4 Hz, 1H), 7.13 (dd, J = 9.3, 2.4 Hz, 1H), 3.29 (septet, J = 6.0 Hz, 1H), 2.81 (s, 3H), 1.39 (d, J = 6.0 Hz, 6H).

10

15

20

Table 1. Summary of the compounds prepared.

Table 1

Compound	X	R ₁	R ₂	R ₃	R ₄	R ₅
1001	N	methyl	H	H	H	H
1002	N	methyl	H	methyl	H	H
1003	N	methyl	H	ethyl	H	H
1004	N	methyl	H	tert-butyl	H	H
1005	N	methyl	H	5-phenoxy-pentyloxy	H	H
1006	N	methyl	H	H	benzyloxy	H
1007	N	methyl	fused	benzene	H	H
1008	N	methyl	H	propyl	H	H
1009	N	methyl	H	octyl	H	H
1010	N	methyl	H	phenyl	H	H
1011	N	methyl	H	OMe	H	H
1012	N	methyl	H	OBu	H	H

Compound	X	R ₁	R ₂	R ₃	R ₄	R ₅
1013	N	methyl	H	Cl	H	H
1014	N	methyl	H	H	Br	H
1015	N	methyl	H	methyl	methyl	H
1016	N	methyl	H	OMe	methyl	H
1017	N	methyl	H	OH	methyl	H
1018	N	methyl	H	OBu	OBu	H
1019	N	methyl	H	F	F	H
1020	N	methyl	H	H	ethyl	H
1021	N	methyl	H	H	isopropyl	H
1022	N	methyl	H	H	tert-butyl	H
1023	N	methyl	H	H	phenyl	H
1024	N	methyl	H	H	OEt	H
1025	N	methyl	H	H	isopropoxy	H
1026	N	methyl	H	Br	H	H
1027	N	ethyl	H	methyl	H	H
1028	N	methyl	H	benzyloxy	H	H
1029	N	methyl	H	cyclohexyl	H	H
1030	N	methyl	H	OCF ₃	H	H
1031	N	methyl	H	pentyl	H	H
1032	N	methyl	H	OPh	H	H
1033	N	methyl	H	4-methylphenyloxy	H	H
1034	N	methyl	H	4-hydroxypentyl	H	H
1035	N	methyl	H	H	1-hydroxyethyl	H

Compound	X	R ₁	R ₂	R ₃	R ₄	R ₅
1036	N	methyl	H	H	OCF ₃	H
1037	N	methyl	H	fused 5,6-	cyclohexenyl	H
1038	N	methyl	H	fused	cyclopentyl	H
1039	N	methyl	H	fused	2,3-furyl	H
2001	N	methyl	H	pentyl	H	H
2002	N	methyl	H	sec-butyl	H	H
2003	N	methyl	H	benzyl	H	H
2004	N	methyl	H	butyl	H	H
2005	N	methyl	H	hexyl	H	H
2006	N	methyl	H	heptyl	H	H
3001	N	methyl	H	H	methyl	H
4001	C	methyl	H	methyl	H	H
4002	C	methyl	H	ethyl	H	H
4003	C	methyl	H	Ph	H	H
4004	C	methyl	H	OMe	H	H
4005	C	methyl	H	Cl	H	H
4006	C	methyl	H	H	methyl	H
4007	C	methyl	H	H	F	H
4008	C	methyl	methyl	H	methyl	H
4009	C	methyl	fused	benzene	H	H
5001	C	methyl	H	butyl	H	H
5002	C	methyl	H	pentyl	H	H
5003	C	methyl	H	hexyl	H	H
6001	C	methyl	H	H	H	H
6002	C	methyl	H	H	H	methyl

118

Compound	X	R ₁	R ₂	R ₃	R ₄	R ₅
6003	C	ethyl	H	H	methyl	H

II. Testing of Chemical Compounds.Test 1

The binding properties of the compounds of the present invention were evaluated at cloned NPFF receptors using protocols described in PCT International Publication No. WO 00/18438, the disclosure of which is hereby incorporated by reference in its entirety into this application.

10

Table 2. Binding affinities at Recombinant Human and Rat NPFF Receptors

NT= Not Tested

15

	hNPFF1	hNPFF2	rNPFF1	rNPFF2
Compound	Ki (nM)	Ki (nM)	Ki (nM)	Ki (nM)
3001	46	1,717	50	1,222
1001	240	2,043	202	>10,000
1007	53	260	146	699
6001	23	374	11	433
4006	13	91	7	185
6003	28	113	21	203
6002	157	952	91	883

20

120

		hNPFF1	hNPFF2	rNPFF1	rNPFF2
	Compound	Ki (nM)	Ki (nM)	Ki (nM)	Ki (nM)
	4005	24	123	25	282
	4009	144	826	153	871
5	4004	113	1,214	153	2,584
	4008	82	514	64	882
	4001	21	150	30	556
	4003	207	2,125	176	1,252
	1020	NT	NT	18	273
10	4007	NT	NT	44	619
	1002	NT	NT	134	3,919
	1019	NT	NT	57	2,874
	1014	NT	NT	300	3,439
	1026	NT	NT	802	>10,000
15	1036	NT	NT	132	2,458
	1013	NT	NT	332	2,019
	1011	NT	NT	201	>10,000
	1021	NT	NT	56	881
	1030	NT	NT	176	4,864
20	2001	50	376	8	221
	1015	NT	NT	42	1,108
	1035	NT	NT	842	1,183
	1003	NT	NT	238	1,638
	2002	NT	NT	77	461
25	1039	NT	NT	68	2,930
	4002	50	232	11	308

	hNPFF1	hNPFF2	rNPFF1	rNPFF2
Compound	Ki (nM)	Ki (nM)	Ki (nM)	Ki (nM)
1012	NT	NT	733	4,845
1028	NT	NT	386	817
5 1032	NT	NT	291	1,638
1029	NT	NT	912	1,201
1031	NT	NT	794	3,223
1033	NT	NT	481	5,864
1004	NT	NT	710	1,488
10 1016	NT	NT	565	2,496
1024	NT	NT	659	5,593
1018	NT	NT	303	1,299
1022	NT	NT	126	602
1017	NT	NT	234	5,919
15 1037	NT	NT	143	824
1008	NT	NT	155	1,121
1038	NT	NT	95	602
1005	NT	NT	316	2,138
2004	NT	NT	392	262
20 2003	NT	NT	371	195
2005	NT	NT	88	268
1006	NT	NT	410	1,071
1010	NT	NT	311	3,480
1009	NT	NT	312	703
25 2006	NT	NT	788	3,674
5002	40	460	30	569

122

	hNPFF1	hNPFF2	rNPFF1	rNPFF2
Compound	Ki (nM)	Ki (nM)	Ki (nM)	Ki (nM)
5003	152	1,172	532	4,423
1034	NT	NT	82	1,537
5001	NT	NT	24	115
1023	228	2,919	4	1,019
1025	NT	NT	253	4,534
1027	NT	NT	606	3,154

10

Test 2

Activity of the compounds of the present invention was measured at cloned NPFF receptors according to functional assays as previously described by Bonini, J. A., et al. (3).

15 Agonist potency (EC_{50}) is the concentration of a compound required to elicit 50% of maximum response. Intrinsic activity of a compound is measured as the percent of maximum response. Intrinsic activity of a compound is measured as the percent of maximum response elicited by the ligand,

20 neuropeptide FF.

Table 3. Agonist Potency (EC_{50}) and Intrinsic Activity (IA) at Recombinant Human (3-1) and Rat (3-2) Neuropeptide FF Receptors

25

123

Table 3-1.

	hNPFF1	hNPFF1	hNPFF2	hNPFF2
Compound	EC ₅₀ (nM)	IA(%NPFF)	EC ₅₀ (nM)	IA(%NPFF)
3001	>10,000	Inactive	>10,000	Inactive
5 6001	>10,000	Inactive	>10,000	Inactive
4006	>10,000	Inactive	>10,000	Inactive
2001	3,453	Inactive	625	84%
4002	>10,000	Inactive	314	69%
5002	>10,000	Inactive	1,707	75%
10 5003	>10,000	Inactive	3,160	45%
1023	>10,000	Inactive	4,114	43%

15

20

Table 3-2.

	rNPFF1	rNPFF1	rNPFF2	rNPFF2
Compound	EC ₅₀ (nM)	IA(%NPFF)	EC ₅₀ (nM)	IA(%NPFF)
1001	>10,000	Inactive	3,084	16%
1007	>10,000	Inactive	1,296	66%
6001	>10,000	Inactive	>10,000	Inactive
4006	>10,000	Inactive	269	32%
6003	>10,000	Inactive	>10,000	Inactive
6002	>10,000	Inactive	>10,000	Inactive
4005	>10,000	Inactive	389	61%
4009	>10,000	Inactive	3,160	70%
4004	>10,000	Inactive	1,528	65%
4008	>10,000	Inactive	411	65%
4001	>10,000	Inactive	404	68%
4003	>10,000	Inactive	3,160	26%
1020	>10,000	Inactive	695	90%
4007	>10,000	Inactive	2,637	17%
1002	>10,000	Inactive	5,621	24%
1019	>10,000	Inactive	2,543	31%
1014	>10,000	Inactive	2,462	47%
1026	>10,000	Inactive	>10,000	19%
1036	>10,000	Inactive	369	78%
1013	>10,000	Inactive	690	52%
1011	>10,000	Inactive	>10,000	Inactive
1021	>10,000	Inactive	283	76%
1030	>10,000	Inactive	625	85%

	rNPFF1	rNPFF1	rNPFF2	rNPFF2
Compound	EC ₅₀ (nM)	IA (%NPFF)	EC ₅₀ (nM)	IA (%NPFF)
2001	242	71%	97	103%
1015	>10,000	Inactive	272	56%
1035	>10,000	Inactive	3,160	52%
1003	>10,000	Inactive	392	83%
2002	250	51%	423	92%
1039	>10,000	Inactive	272	78%
4002	>10,000	Inactive	125	84%
1012	>10,000	Inactive	1,616	80%
1028	>10,000	Inactive	758	79%
1032	374	31%	459	93%
1029	>10,000	28%	2,046	31%
1031	>10,000	Inactive	2,187	66%
1033	>10,000	Inactive	3,160	51%
1004	1,469	36%	440	90%
1016	>10,000	Inactive	3,160	74%
1024	>10,000	Inactive	>10,000	Inactive
1018	>10,000	Inactive	>10,000	Inactive
1022	3,160	19%	190	81%
1017	>10,000	Inactive	>10,000	23%
1037	>10,000	Inactive	3,160	71%
1008	>10,000	Inactive	619	85%
1038	>10,000	Inactive	48	74%
1005	>10,000	Inactive	3,160	21%
2004	194	40%	124	101%

126

	rNPFF1	rNPFF1	rNPFF2	rNPFF2
Compound	EC ₅₀ (nM)	IA (%NPFF)	EC ₅₀ (nM)	IA (%NPFF)
2003	171	56%	49	89%
2005	137	56%	105	81%
5 1006	>10,000	15%	1,080	22%
1010	>10,000	Inactive	>10,000	22%
1009	1,494	Inactive	5,621	22%
2006	886	38%	1,953	47%
5002	157	41%	259	90%
10 5003	440	27%	9,993	57%
1034	610	63%	394	101%
5001	123	28%	69	82%
1023	>10,000	Inactive	3,160	35%
1025	>10,000	Inactive	3,160	27%
15 1027	>10,000	Inactive	>10,000	31%

Test 3

20 Methods for two NPFF2 selective compounds that were tested in vivo experiment

The effects of compounds on the micturition reflex were assessed in the "distension-induced rhythmic contraction" (DIRC) model (also called "volume-induced rhythmic

25

contraction" model) in rats, as described in previous publications (36, 38, 40). This model is widely considered to be predictive for the actions of drugs to treat human urge incontinence (also referred to as detrusor instability or unstable bladder). Examples of drugs that are active in this model which also are used therapeutically in humans include oxybutynin and baclofen (40); imipramine and nortriptyline (37); and nifedipine and terodiline (38).

10 *DIRC Model*

Female Sprague Dawley rats weighing approximately 300g were anesthetized with subcutaneous urethane (1.2g/kg). The trachea was cannulated with PE240 tubing to provide a clear airway throughout the experiment. A midline abdominal incision was made and the left and right ureters were isolated. The ureters were ligated distally (to prevent escape of fluids from the bladder) and cannulated proximally with PE10 tubing. The incision was closed using 4-0 silk sutures, leaving the PE10 lines routed to the exterior for the elimination of urine. The bladder was canulated via the transurethral route using PE50 tubing inserted 2.5cm beyond the urethral opening. This cannula was secured to the tail using tape and connected to a pressure transducer. To prevent leakage from the bladder, the cannula was tied tightly to the exterior urethral opening using 4-0 silk.

To initiate the micturition reflex, the bladder was first

128

emptied by applying pressure to the lower abdomen, and then filled with normal saline in 100 μ L increments (maximum = 2ml) until spontaneous bladder contractions occurred (typically 20-40 mmHg) at a rate of one contraction every 2 to 3 minutes. Once a regular rhythm was established, vehicle (saline) or test compounds were administered i.v. to examine their effects on bladder activity. The effect of a compound which inhibited the micturition reflex was expressed as its "disappearance time", defined as the time between successive bladder contractions in the presence of the test compound minus the time between contractions before compound administration.

Results of Test 3

Compound X (4005) at a dose of 1mg/kg, i.v. produced complete inhibition of distention induced contractions of the rat bladder, resulting in a disappearance time of 35 minutes. Compound Y (4006) at a dose of 3mg/kg, i.v. produced complete inhibition of distention induced contractions of the rat bladder, resulting in a disappearance time of 12 minutes.

Discussion of Test 3

These results represent the first demonstration that synthetic ligands which are active as agonists at the NPFF2 receptor inhibit the micturition reflex. In this regard their actions

mimic the action of the endogenous peptide ligand NPFF. The ability of these compounds to inhibit the micturition reflex in this model can be taken as an indication that they will be effective in the treatment of urge incontinence in humans (see
5 above).

10

15

20

DISCUSSION

The compounds discussed above can be classified as agonists and antagonists based on the following parameters: an agonist
5 has an intrinsic activity (IA) >15%, while an antagonist has a $K_i \leq 1.2 \mu\text{M}$ and an intrinsic activity (IA) $\leq 15\%$ at the rat cloned neuropeptide FF (NPFF) receptors.

Based on this definition the compounds can be classified as
10 follows:

Compounds 1001 to 1039 are quinazolino-guanidines that are antagonists at NPFF1 and agonists at NPFF2;

15 Compounds 2001 to 2006 are quinazolino-guanidines that are concurrently agonists at NPFF1 and NPFF2;

Compound 3001 is quinazolino-guanidines that is concurrently antagonists at NPFF1 and NPFF2;

20

Compounds 4001 to 4009 are quinolino-guanidines that are antagonists at NPFF1 and agonists at NPFF2;

Compounds 5001 to 5003 are quinolino-guanidines that are concurrently agonists at NPFF1 and NPFF2; and

5 Compounds 6001 to 6003 are quinolino-guanidines that are concurrently antagonists at NPFF1 and NPFF2.

Compounds that are agonists at NPFF2 are suitable for treating incontinence, and also pain.

10 Compounds that are concurrently agonists at both NPFF1 and NPFF2 are particularly suitable for treating incontinence, and also pain.

15 Compounds that are concurrently antagonists at both NPFF1 and NPFF2 have a pro-opioid (analgesic) effect.

Compounds that are agonists at NPFF1 are suitable for treating obesity or eating disorders.

20 When comparing the binding affinities of compounds between the human and rat recombinant NPFF receptors, one obtains a positive correlation with slope values close to unity, the line of identity. These data suggest that the binding affinity for a compound at the rat receptor will be predictive

132

of its binding affinity at the human recombinant receptor.

5

10

15

20

REFERENCES

1. Yang, H.Y., Fratta, W., Majane, E.A., and Costa, E.
Isolation, sequencing, synthesis, and pharmacological
5 characterization of two brain neuropeptides that
modulate the action of morphine.
Proc.Natl.Acad.Sci.U.S.A. 82(22):7757-7761, 1985.
2. Vilim, E.S., Ziff, E. Cloning of the neuropeptide NPFF
10 and NPAF precursor form bovine, rat, mouse, and human.
Soc. Neurosci. 21:760, 1995.
3. Bonini, J. A., Jones, K. A., Adham, N., Forray, C.,
Artymyshyn, R., Durkin, M. M., Smith, K. E., Tamm, J. A.,
15 Boteju, L. W., Lakhlani, P. P., Raddatz, R., Yao, W-J.,
Ogozaleck, K. L., Boyle, N., Kouranova, E. V., Quan, Y.,
Vyase, P. J., Wetzel, J. M., Branchek, T. A., Gerald, C.,
Borowsky, B. Identification and characterization of two
G protein-coupled receptors for neuropeptide FF. *J.*
20 *Biol. Chem.* 275(50): 39324-31, 2000.
4. DNA Encoding Mammalian Neuropeptide FF (NPFF) Receptors
and Uses Thereof, PCT International Publication No. WO
00/18438.

5. Panula, P., Aarnisalo, A.A., and Wasowicz, K. Neuropeptide FF, a mammalian neuropeptide with multiple functions [published erratum appears in *Prog. Neurobiol.* 1996 Jun; 49(3):285]. *Prog. Neurobiol.* 48(4-5):461-487, 1996.
6. Roumy, M. and Zajac, J.M. Neuropeptide FF, pain and analgesia. *Eur.J.Pharmacol.* 345(1):1-11, 1998.
7. Payza, K., Akar, C.A., and Yang, H.Y. Neuropeptide FF receptors: structure-activity relationship and effect of morphine. *J.Pharmacol.Exp.Ther.* 267(1):88-94, 1993.
8. Raffa, R.B., Kim, A., Rice, K.C., de Costa, B.R., Codd, E.E., and Rothman, R.B. Low affinity of FMRFamide and four FaRPs (FMRFamide-related peptides), including the mammalian-derived FaRPs F-8-Famide (NPFF) and A-18-Famide, for opioid mu, delta, kappa 1, kappa 2a, or kappa 2b receptors. *Peptides* 15(3):401-404, 1994.
9. Malin, D.H., Lake, J.R., Arcangeli, K.R., Deshotel, K.D., Hausam, D.D., Witherspoon, W.E., Carter, V.A., Yang, H.Y., Pal, B., and Burgess, K. Subcutaneous injection of an analog of neuropeptide FF precipitates morphine abstinence syndrome. *Life Sci.* 53(17):PL261-6, 1993.

10. Malin, D.H., Lake, J.R., Fowler, D.E., Hammond, M.V.,
Brown, S.L., Leyva, J.E., Prasco, P.E., and Dougherty,
T.M. FMRF-NH₂-like mammalian peptide precipitates opiate-
withdrawal syndrome in the rat. *Peptides* 11(2):277-280,
5 1990.
11. Panula, P., Kivipelto, L., Nieminen, O., Majane, E.A.,
and Yang, H.Y. Neuroanatomy of morphine-modulating
peptides. *Med.Biol.* 65(2-3):127-135, 1987.
- 10 12. Allard, M., Geoffre, S., Legendre, P., Vincent, J.D., and
Simonnet, G. Characterization of rat spinal cord
receptors to FLFQPQRFamide, a mammalian morphine
modulating peptide: a binding study. *Brain Res.* 500(1-
15 2):169-176, 1989.
13. Allard, M., Zajac, J.M., and Simonnet, G.
Autoradiographic distribution of receptors to
FLFQPQRFamide, a morphine-modulating peptide, in rat
20 central nervous system. *Neuroscience* 49(1):101-116, 1992.
14. Gouarderes, C., Tafani, J.A.M., and Zajac, J.M. Affinity
of neuropeptide FF analogs to opioid receptors in the rat
spinal cord. *Peptides* 19(4):727-730, 1998.

15. Payza, K. and Yang, H.Y. Modulation of neuropeptide FF receptors by guanine nucleotides and cations in membranes of rat brain and spinal cord. *J.Neurochem.* 60(5):1894-1899, 1993.
- 5
16. Gouarderes, C., Sutak, M., Zajac, J.M., and Jhamandas, K. Antinociceptive effects of intrathecally administered F8Famide and FMRFamide in the rat. *Eur.J.Pharmacol.* 237(1):73-81, 1993.
- 10
17. Yang, H. Y. T., Martin, B. M. *Soc. Neurosci.* 21, 760, 1995.
18. Jhamandas, K., Sutak, M., Yang, H. -Y. T. *Soc. Neurosci.* 22, 1313, 1996.
- 15
19. Kontinen, V.K., Aarnisalo, A.A., Idaenpaeaen-Heikkilae, J.J., Panula, P., and Kalso, E. Neuropeptide FF in the rat spinal cord during carrageenan inflammation. *Peptides* 18(2):287-292, 1997.
- 20
20. Wei, H., Panula, P., and Pertovaara, A. A differential modulation of allodynia, hyperalgesia and nociception by neuropeptide FF in the periaqueductal gray of neuropathic rats: Interactions with morphine and naloxone.
- 25

Neuroscience 86(1):311-319, 1998.

21. Oberling, P., Stinus, L., Le Moal, M., and Simonnet, G.
Biphasic effect on nociception and antioptive activity of
the neuropeptide FF (FLFQPQRFamide) in the rat. *Peptides*
14(5):919-924, 1993.
22. Gouarderes, C., Jhamandas, K., Sutak, M., and Zajac, J.M.
Role of opioid receptors in the spinal antinociceptive
effects of neuropeptide FF analogues. *Br.J.Pharmacol.*
117(3):493-501, 1996.
23. Gouarderes, C., Kar, S., Zajac, J. -M., *Neuroscience*, 74,
21-27, 1996.
24. Xu, M.; Kontinen, V. K.; Panula, P.; Kalso, E. *Peptides*,
10, 1071-1077, 1999.
25. Coudoré, M. A.; Courteix, C.; Eschaliér, A.; Zajac, J. -
M., Wilcox, G. L.; Fialip, J. *Resumes de la lere Reunion*
de la Societe Francaise de Pharmacologie (Marseilles,
France), vol. 17, p23, 1997.
26. Huang, E. Y. -K.; Li, J. Y.; Tan, P. P. -C.; Wong, C. -

H.; Chen, J. -C. *Peptides*, 21, 205-210, 2000.


27. Robert, J.J., Orosco, M., Rouch, C., Jacquot, C., and Cohen, Y. Unexpected responses of the obese "cafeteria" rat to the peptide FMRF-amide. *Pharmacol.Biochem.Behav.* 34(2):341-344, 1989.
28. Murase, T., Arima, H., Kondo, K., and Oiso, Y. Neuropeptide FF reduces food intake in rats. *Peptides* 17(2):353-354, 1996.
29. Kavaliers, M., Hirst, M., and Mathers, A. Inhibitory influences of FMRFamide on morphine- and deprivation-induced feeding. *Neuroendocrinology*. 40(6):533-535, 1985.
30. Payza, K. and Yang, H.Y. Modulation of neuropeptide FF receptors by guanine nucleotides and cations in membranes of rat brain and spinal cord. *J.Neurochem.* 60(5):1894-1899, 1993.
31. Devillers, J.P., Mazarguil, H., Allard, M., Dickenson, A.H., Zajac, J.M., and Simonnet, G. Characterization of a potent agonist for NPFF receptors: binding study on rat spinal cord membranes. *Neuropharmacology* 33(5):661-669, 1994.

32. Cowan, J. A., (1986) "Cu²⁺/BH₄- Reduction System: Synthetic Utility And Mode of Action", *Tetrahedron Lett* 27 pages 1205-1208.
- 5 33. a) Brown, J. P., (1964) "Reactions of 2,2-Dialkyl-1,2-dihydroquinolines, Part I. Preparation of 2-Guanidinoquinazolines", *J. Chem. Soc.* Pages 3012-3016.
b) Hamann, L. G., et al, (1998) "Synthesis and Biological Activity of a Novel Series of
10 Nonsteroidal, Peripherally Selective Androgen Receptor Antagonists Derived from 1,2-Dihydropyridono[5,6-g]quinolines", *J. Med. Chem.* 41 pages 623-639.
- 15 34. Hynes, J. B. and Campbell, J. P., (1997) "2-Aminoquinazolines", *J. Heterocycl. Chem.* 34(2) pages 385-387.
35. Kuhla, D. E., et al, (1986) "Quinoline and Quinazoline Derivatives for Treating Gastrointestinal Motility Dysfunctions", US Patent No. 4,563,460.
- 20 36. Maggi, C.A, Furio, M., Santicioli, P., Conte, B. and Meli, A. (1987) "Spinal and supraspinal components of GABAergic inhibition of the micturition reflex in rats. *J. Pharmacol Exp Ther* 240, 998-1005.
- 25

37. Pietra, C., Poggesi, E., Angelico, P., Guarneri, L. and
Testa, R. Effects of some antidepressants on the
volume-induced reflex contractions of the rat urinary
bladder: lack of correlation with muscarinic receptors
affinity. *Pharmacological Research*, 22: 421-432, 1990.
38. Guarneri, L., Ibba, M., Angelico, P., Colombo, D.,
Fredella, B. and Testa, R. Effects of drugs used in the
therapy of detrusor hyperactivity on the volume-induced
contractions of the rat urinary bladder. *Pharmacological
Research*, 27: 173-187, 1993.
39. Morgan, D.G., Small, C.J., Abusnana, S., Turton, M.,
Gunn, I., Heath, M., Rossi, M., Goldstone, A.P., O'Shea,
D., Meeran, K., Ghatei, M., Smith, D. M., and Bloom, S.
The NPY Y1 receptor antagonist BIBP 3226 blocks NPY
induced feeding via a non-specific mechanism. *Regul.
Pept.* 75-76: 377-382, 1998.
40. Morikawa, K., Hashimoto, S., Yamauchi, T., Kato, H., Ito,
Y., and Gomi, Y. (1992) "Inhibitory effect of inaperisone
hydrochloride (inaperisone), a new centrally acting
muscle relaxant, on the micturition reflex" *Eur J
pharmacol* 213, 409-415.

What is claimed is:

1. A method of treating urge incontinence in a subject in need of such treatment comprising administering to the subject an effective amount of a compound having the structure:



wherein X = CH, C(CH₃) or N;

wherein each of R₁, R₂, R₃, R₄ and R₅ is independently H, C₁-C₁₀ straight chained or branched alkyl, C₂-C₁₀ straight chained or branched alkenyl, C₂-C₁₀ straight chained or branched alkynyl, C₃-C₁₀ cycloalkyl, substituted or unsubstituted aryl, hydroxy, halogenated ether, nitro, amino, halogen, -CN, -C(=Z)R₆, -C(=Z)OR₆, -C(=Z)N(R₆)₂, -N(R₆)-C(=Z)R₆, -N(R₆)-C(=Z)N(R₆)₂, -OC(=Z)R₆, -C(=Z)OR₆, -OR₆ or -SR₆;

wherein Z is O or S; and

wherein R₆ is C₁-C₁₀ straight chained or branched alkyl, aryl, (CH₂)_nQ, C₂-C₁₀ alkenyl, C₃-C₁₀ cycloalkyl, C₅-C₁₀ cycloalkenyl,

wherein Q is OR₇, SR₇, N(R₇)₂ or aryl,

wherein R₇ is H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl,

wherein R₂ and R₃ and the carbons to which they are attached form

a fused aryl, heteroaryl, C₅-C₁₀ cyclic alkyl or heterocyclic alkyl ring; or wherein R₃ and R₄ and the carbons to which they are attached form a fused aryl, heteroaryl, cyclic alkyl or heterocyclic alkyl ring;

and wherein each alkyl, alkenyl, alkynyl and alkoxy group is optionally substituted with a substituent independently selected from R_a, where R_a is

- 1) hydroxy,
- 2) C₁-C₁₀ alkoxy,
- 3) halogen,
- 4) nitro,
- 5) amino,
- 6) CF₃, or
- 7) carboxy,

and each cycloalkyl group is optionally substituted with a substituent independently selected from R_b, where R_b is

- 1) a group selected from R_a,
- 2) C₁-C₇ alkyl,
- 3) C₂-C₇ alkenyl,
- 4) C₂-C₇ alkynyl or
- 5) cyclic C₁-C₁₀ alkyl,

and each aryl is optionally substituted with R₁,
to thus treat the urge incontinence in the subject.

2. The method of claim 1, wherein R_1 is methyl or ethyl;

wherein R_2 is H or fused benzene;

wherein R_3 is H, methyl, ethyl, propyl, tert-butyl, octyl, cyclohexyl, phenyl, hydroxy, methoxy, butoxy, pentoxy, phenoxy, benzoxy, trifluoromethyl ether, methylbenzene ether, 5-phenoxypentyloxy, 4-Hydroxypentyl, Cl, Br, F, or wherein R_2 and R_3 and the carbons to which they are attached form a fused benzene, fused 5,6-cyclohexenyl, fused cyclopentyl, or fused 2,3-furyl; and

wherein R_4 is H, methyl, ethyl, isopropyl, tert-butyl, 1-hydroxyethyl, ethoxy, butoxy, isopropoxy, phenoxy, benzyloxy, trifluoromethyl ether, Br, F, or wherein R_3 and R_4 and the carbons to which they are attached form a fused benzene, fused 5,6-cyclohexenyl, fused cyclopentyl, or fused 2,3-furyl.

3. The method of claim 1, wherein R_1 is methyl or ethyl;

wherein R_2 is H;

wherein R_3 is propyl, octyl, cyclohexyl, phenyl, hydroxy, methoxy, butoxy, pentoxy, phenoxy, benzoxy, trifluoromethyl ether, methylbenzene ether, 4-Hydroxypentyl, Cl, Br, F, or wherein R_2 and R_3 and the carbons to which they are attached form fused 5,6-cyclohexenyl, fused cyclopentyl, or fused 2,3-furyl; and

wherein R_4 is H, methyl, ethyl, isopropyl, tert-butyl, 1-hydroxy

ethyl, ethoxy, butoxy, isopropoxy, phenyl, Br, F, or wherein R_3 and R_4 and the carbons to which they are attached form a fused 5,6-cyclohexenyl, fused cyclopentyl, or fused 2,3-furyl.

4. The method of claim 1, wherein R_1 is methyl or ethyl;

wherein R_2 is H;

wherein R_3 is cyclohexyl, benzoxy, pentoxy, phenoxy, trifluoromethyl ether, methylbenzene ether, 4-hydroxypentyl, or wherein R_2 and R_3 and the carbons to which they are attached form fused 5,6-cyclohexenyl, fused cyclopentyl, or fused 2,3-furyl; and

wherein R_4 is H, 1-hydroxyethyl, trifluoromethyl ether, or wherein R_3 and R_4 and the carbons to which they are attached form fused 5,6-cyclohexenyl, fused cyclopentyl or fused 2,3-furyl.


5. The method of claim 2, wherein R_1 is methyl or ethyl;

wherein R_2 is H;

wherein R_3 is cyclohexyl, pentoxy, phenoxy, trifluoromethyl ether, methylbenzene ether, 4-hydroxypentyl, or wherein R_2 and R_3 and the carbons to which they are attached form fused 5,6-cyclohexenyl, fused cyclopentyl, or fused 2,3-furyl;

wherein R_4 is H, 1-hydroxyethyl, trifluoromethyl ether, or wherein R_3 and R_4 and the carbons to which they are attached form fused 5,6-cyclohexenyl, fused cyclopentyl, or fused 2,3-furyl.

6. The method of claim 1, wherein the compound has the structure:




wherein R₃ is H, straight chained or branched C₁-C₇ alkyl or aryl.

7. The method of claim 6, wherein R₃ is butyl, sec-butyl, pentyl, hexyl, heptyl, or benzyl.

8. The method of claim 7, wherein R₃ is butyl, sec-butyl, hexyl, heptyl, or benzyl.

9. The method of claim 1, wherein the compound has the structure:




wherein R₄ is H, straight chained or branched C₁-C₇ alkyl.

10. The method of claim 10, wherein R₄ is H, or methyl.

146

11. The method of claim 1, wherein the compound has the structure:



wherein R₂ is H or methyl;

wherein R₃ is H, straight chained or branched C₁-C₇ alkyl, aryl, alkoxy or halogen, or wherein R₂ and R₃ and the carbons to which they are attached form a fused aryl; and

wherein R₄ is H, methyl or halogen.


12. The method of claim 11, wherein R₂ is H, methyl;

wherein R₃ is H, Cl, methyl, ethyl, methoxy, phenyl or wherein R₂ and R₃ and the carbons to which they are attached form fused benzene; and

wherein R₄ is H, methyl or F.

147


13. The method of claim 1, wherein the compound has the structure:



wherein R_3 is H, straight chained or branched C_1 - C_7 alkyl.

14. The method of claim 14, wherein R_3 is butyl, pentyl or hexyl.

15. The method of claim 1, wherein the compound has the structure:




wherein R_1 is H, straight chained or branched C_1 - C_7 alkyl; and

wherein each R_4 and R_5 is independently H or straight chained or branched C_1 - C_7 alkyl.


148

16. The method of claim 16, wherein R_1 is methyl or ethyl; and
wherein each R_4 and R_5 is independently H or methyl.

17. The method of claim 1, wherein the compound has the structure:




18. The method of claim 1, wherein the compound has the structure:




149


19. The method of claim 1, wherein the compound has the structure:




20. The method of claim 1, wherein the compound has the structure:




21. The method of claim 1, wherein the compound has the structure:



22. The method of claim 1, wherein the compound has the structure:




23. The method of claim 1, wherein the compound has the structure:




151


24. The method of claim 1, wherein the compound has the structure:




25. The method of claim 1, wherein the compound has the structure:




26. The method of claim 1, wherein the compound has the structure:




27. The method of claim 1, wherein the compound has the structure:




28. The method of claim 1, wherein the compound has the structure:




29. The method of claim 1, wherein the compound has the structure:




30. The method of claim 1, wherein the compound has the structure:




31. The method of claim 1, wherein the compound has the structure:




32. The method of claim 1, wherein the compound has the structure:




33. The method of claim 1, wherein the compound has the structure:




34. The method of claim 1, wherein the compound has the structure:




35. The method of claim 1, wherein the compound has the structure:




36. The method of claim 1, wherein the compound has the structure:




37. The method of claim 1, wherein the compound has the structure:




38. The method of claim 1, wherein the compound has the structure:




39. The method of claim 1, wherein the compound has the structure:



40. The method of claim 1, wherein the compound has the structure:




41. The method of claim 1, wherein the compound has the structure:




157


42. The method of claim 1, wherein the compound has the structure:




43. The method of claim 1, wherein the compound has the structure:




44. The method of claim 1, wherein the compound has the structure:




45. The method of claim 1, wherein the compound has the structure:



46. The method of claim 1, wherein the compound has the structure:




47. The method of claim 1, wherein the compound has the structure:




159


48. The method of claim 1, wherein the compound has the structure:



49. The method of claim 1, wherein the compound has the structure:




50. The method of claim 1, wherein the compound has the structure:




160


51. The method of claim 1, wherein the compound has the structure:



52. The method of claim 1, wherein the compound has the structure:




53. The method of claim 1, wherein the compound has the structure:




161


54. The method of claim 1, wherein the compound has the structure:




55. The method of claim 1, wherein the compound has the structure:




56. The method of claim 6, wherein the compound has the structure:




57. The method of claim 6, wherein the compound has the structure



58. The method of claim 6, wherein the compound has the structure:




59. The method of claim 6, wherein the compound has the structure:




163


60. The method of claim 6, wherein the compound has the structure:



61. The method of claim 6, wherein the compound has the structure:




62. The method of claim 9, wherein the compound has the structure:




164


63. The method of claim 11, wherein the compound has the structure:



64. The method of claim 11, wherein the compound has the structure:




65. The method of claim 11, wherein the compound has the structure:




165


66. The method of claim 11, wherein the compound has the structure:



67. The method of claim 11, wherein the compound has the structure:




68. The method of claim 11, wherein the compound has the structure:




166


69. The method of claim 11, wherein the compound has the structure:



70. The method of claim 11, wherein the compound has the structure:




71. The method of claim 11, wherein the compound has the structure:




167


72. The method of claim 13, wherein the compound has the structure:



73. The method of claim 13, wherein the compound has the structure:




74. The method of claim 13, wherein the compound has the structure:




168


75. The method of claim 15, wherein the compound has the structure:



76. The method of claim 15, wherein the compound has the structure:




77. The method of claim 15, wherein the compound has the structure:



169

78. A method of treating pain in a subject in need of such treatment comprising administering to the subject an effective amount of a compound having the structure:



wherein X = CH, C(CH₃) or N;

wherein each of R₁, R₂, R₃, R₄ and R₅ is independently H, C₁-C₁₀ straight chained or branched alkyl, C₂-C₁₀ straight chained or branched alkenyl, C₂-C₁₀ straight chained or branched alkynyl, C₃-C₁₀ cycloalkyl, substituted or unsubstituted aryl, hydroxy, halogenated ether, nitro, amino, halogen, -CN, -C(=Z)R₆, -C(=Z)OR₆, -C(=Z)N(R₆)₂, -N(R₆)-C(=Z)R₆, -N(R₆)-C(=Z)N(R₆)₂, -OC(=Z)R₆, -C(=Z)OR₆ -OR₆ or -SR₆;

wherein Z is O or S; and

wherein R₆ is C₁-C₁₀ straight chained or branched alkyl, aryl, (CH₂)_nQ, C₂-C₁₀ alkenyl, C₃-C₁₀ cycloalkyl, C₃-C₁₀ cycloalkenyl,

wherein Q is OR₇, SR₇, N(R₇)₂ or aryl,

wherein R₇ is H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl,

wherein R₂ and R₃ and the carbons to which they are attached form a fused aryl, heteroaryl, C₅-C₁₀ cyclic alkyl or heterocyclic alkyl

ring; or wherein R_3 and R_4 and the carbons to which they are attached form a fused aryl, heteroaryl, cyclic alkyl or heterocyclic alkyl ring;

and wherein each alkyl, alkenyl, alkynyl and alkoxy group is optionally substituted with a substituent independently selected from R_a , where R_a is

- 1) hydroxy,
- 2) C_1 - C_{10} alkoxy,
- 3) halogen,
- 4) nitro,
- 5) amino,
- 6) CF_3 , or
- 7) carboxy,


and each cycloalkyl group is optionally substituted with a substituent independently selected from R_b , where R_b is

- 1) a group selected from R_a ,
- 2) C_1 - C_7 alkyl,
- 3) C_2 - C_7 alkenyl,
- 4) C_2 - C_7 alkynyl or
- 5) cyclic C_1 - C_{10} alkyl,

and each aryl is optionally substituted with R_1 ,
to thus treat pain in the subject:

171

79. A compound having the structure:



wherein each of R_1 , R_2 , R_3 , R_4 and R_5 is independently H, C_1 - C_{10} straight chained or branched alkyl, C_2 - C_{10} straight chained or branched alkenyl, C_2 - C_{10} straight chained or branched alkynyl, C_3 - C_{10} cycloalkyl, substituted or unsubstituted aryl, hydroxy, halogenated ether, nitro, amino, halogen, $-CN$, $-C(=Z)R_6$, $-C(=Z)OR_6$, $-C(=Z)N(R_6)_2$, $-N(R_6)-C(=Z)R_6$, $-N(R_6)-C(=Z)N(R_6)_2$, $-OC(=Z)R_6$, $-C(=Z)OR_6$, $-OR_6$ or $-SR_6$;

wherein Z is O or S; and

wherein R_6 is C_1 - C_{10} straight chained or branched alkyl, aryl, $(CH_2)_nQ$, C_2 - C_{10} alkenyl, C_3 - C_{10} cycloalkyl, C_5 - C_{10} cycloalkenyl,

wherein Q is OR_7 , SR_7 , $N(R_7)_2$ or aryl,

wherein R_7 is H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl,

wherein R_2 and R_3 and the carbons to which they are attached form a fused aryl, heteroaryl, C_5 - C_{10} cyclic alkyl or heterocyclic alkyl ring; or wherein R_3 and R_4 and the carbons to which they are attached form a fused aryl, heteroaryl, cyclic alkyl or heterocyclic alkyl ring;

and wherein each alkyl, alkenyl, alkynyl and alkoxy group is optionally substituted with a substituent independently selected from R_a , where R_a is


- 1) hydroxy,
- 2) C_1 - C_{10} alkoxy,
- 3) halogen,
- 4) nitro,
- 5) amino,
- 6) CF_3 , or
- 7) carboxy,

and each cycloalkyl group is optionally substituted with a substituent independently selected from R_b , where R_b is

- 1) a group selected from R_a ,
- 2) C_1 - C_7 alkyl,
- 3) C_2 - C_7 alkenyl,
- 4) C_2 - C_7 alkynyl or
- 5) cyclic C_1 - C_{10} alkyl,

and each aryl is optionally substituted with R_1 .

80. The compound of claim 79, having the structure:



wherein R_2 is H or methyl;

173

wherein R_3 is H, straight chained or branched C_1 - C_7 alkyl, aryl, alkoxy or halogen, or wherein R_2 and R_3 and the carbons to which they are attached form a fused aryl; and


wherein R_4 is H, methyl or halogen.

81. The compound of claim 79, wherein R_2 is H, methyl;

wherein R_3 is H, Cl, methyl, ethyl, methoxy, phenyl or wherein R_2 and R_3 and the carbons to which they are attached form fused benzene; and

wherein R_4 is H, methyl or F.

82. The compound of claim 79 having the structure:




wherein R_3 is H, straight chained or branched C_1 - C_7 alkyl.

83. The compound of claim 82, wherein R_3 is propyl, pentyl or hexyl.

174

84. The compound of claim 79 having the structure:




wherein R₁ is H, straight chained or branched C₁-C₇ alkyl; and

wherein each R₄ and R₅ is independently H or straight chained or branched C₁-C₇ alkyl.

85. The compound of claim 84, wherein R₁ is methyl or ethyl; and

wherein each R₄ and R₅ is independently H or methyl.

86. A compound having the structure:



wherein each of R₁, R₂, R₄ and R₅ is independently H, C₁-C₁₀ straight chained or branched alkyl, C₂-C₁₀ straight chained or branched alkenyl, C₂-C₁₀ straight chained or branched alkynyl, C₃-C₁₀

cycloalkyl, substituted or unsubstituted aryl, hydroxy, halogenated ether, nitro, amino, halogen, -CN, -C(=Z)R₆, -C(=Z)OR₆, -C(=Z)N(R₆)₂, -N(R₆)-C(=Z)R₆, -N(R₆)-C(=Z)N(R₆)₂, -OC(=Z)R₆, -C(=Z)OR₆-OR₆ or -SR₆;

wherein Z is O or S; and

wherein R₆ is C₁-C₁₀ straight chained or branched alkyl, aryl, (CH₂)_nQ, C₂-C₁₀ alkenyl, C₃-C₁₀ cycloalkyl, C₅-C₁₀ cycloalkenyl,

wherein Q is OR₇, SR₇, N(R₇)₂ or aryl,

wherein R₇ is H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl,

wherein R₃ is straight chained C₃, C₄, C₆ or C₇ alkyl or branched C₅-C₇ alkyl, C₂-C₁₀ straight chained or branched alkenyl, C₂-C₁₀ straight chained or branched alkynyl, C₃-C₁₀ cycloalkyl, substituted or unsubstituted aryl, hydroxy, halogenated ether, nitro, amino, halogen, -CN, -C(=Z)R₆, -C(=Z)OR₆, -C(=Z)N(R₆)₂, -N(R₆)-C(=Z)R₆, -N(R₆)-C(=Z)N(R₆)₂, -OC(=Z)R₆, -C(=Z)OR₆-OR₆ or -SR₆;

wherein Z is O or S; and

wherein R₆ is C₁-C₁₀ straight chained or branched alkyl, aryl, (CH₂)_nQ, C₂-C₁₀ alkenyl, C₃-C₁₀ cycloalkyl, C₅-C₁₀ cycloalkenyl,

wherein Q is OR₇, SR₇, N(R₇)₂ or aryl,

wherein R₇ is H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl,

wherein R₂ and R₃ and the carbons to which they are attached form a fused cyclic alkyl or heterocyclic alkyl ring; or wherein R₃ and R₄ and the carbons to which they are attached form a fused aryl, heteroaryl, cyclic alkyl or heterocyclic alkyl ring; and

and wherein each alkyl, alkenyl, alkynyl and alkoxy group is optionally substituted with a substituent independently selected from R_a , where R_a is


- 1) hydroxy,
- 2) C_1 - C_{10} alkoxy,
- 3) halogen,
- 4) nitro,
- 5) amino,
- 6) CF_3 , or
- 7) carboxy,

and each cycloalkyl group is optionally substituted with a substituent independently selected from R_b , where R_b is

- 1) a group selected from R_a ,
- 2) C_1 - C_7 alkyl,
- 3) C_2 - C_7 alkenyl,
- 4) C_2 - C_7 alkynyl or
- 5) cyclic C_1 - C_{10} alkyl,

and each aryl is optionally substituted with R_1 .

87. The compound of claim 86 having the structure:



wherein R_1 is H, straight chained or branched C_1 - C_7 alkyl;

wherein R_2 is H, straight chained or branched C_1 - C_7 alkyl or fused

aryl;

wherein R_3 is straight chained C_3 , C_4 , C_6 or C_7 alkyl or branched C_5 - C_7 alkyl, cycloalkyl, substituted or unsubstituted aryl, hydroxyl, straight chained or branched alkoxy, halogenated ether, or halogen;

wherein R_4 is H, branched C_1 - C_7 alkyl, aryl, straight chained or branched alkoxy or halogen; or wherein R_2 and R_3 and the carbons to which they are attached form a fused C_3 - C_6 cyclic alkyl or heterocyclic alkyl ring; or wherein R_3 and R_4 and the carbons to which they are attached form a fused C_6 - C_7 aryl or heteroaryl ring, a fused C_3 - C_6 cyclic alkyl or heterocyclic alkyl ring.

88. The compound of claim 86, wherein R_1 is methyl or ethyl;

wherein R_2 is H or fused benzene;

wherein R_3 is cyclohexyl, phenyl, hydroxy, methoxy, butoxy, pentoxy, phenoxy, benzoxy, trifluoromethyl ether, methylbenzene ether, 4-Hydroxypentyl, Cl, Br, F, or wherein R_2 and R_3 and the carbons to which they are attached form fused 5,6-cyclohexenyl, fused cyclopentyl, or fused 2,3-furyl; and

wherein R_4 is H, isopropyl, tert-butyl, 1-hydroxyethyl, ethoxy, butoxy, isopropoxy, phenyl, Br, F, or wherein R_3 and R_4 and the carbons to which they are attached form fused 5,6-cyclohexenyl, fused cyclopentyl, or fused 2,3-furyl.

89. The compound of claim 86, wherein R_1 is methyl or ethyl;

wherein R_2 is H or fused benzene;

wherein R_3 is cyclohexyl, benzoxy, pentoxy, phenoxy, trifluoromethyl ether, methylbenzene ether, 4-hydroxypentyl, or wherein R_2 and R_3 and the carbons to which they are attached form fused 5,6-cyclohexenyl, fused cyclopentyl, or fused 2,3-furyl; and

wherein R_4 is H, 1-hydroxyethyl, trifluoromethyl ether, or wherein R_3 and R_4 and the carbons to which they are attached form fused 5,6-cyclohexenyl, fused cyclopentyl or fused 2,3-furyl.


90. The compound of claim 86, wherein R_1 is methyl or ethyl;

wherein R_2 is H or fused benzene;

wherein R_3 is cyclohexyl, pentoxy, phenoxy, trifluoromethyl ether, methylbenzene ether, 4-hydroxypentyl, or wherein R_2 and R_3 and the carbons to which they are attached form fused 5,6-cyclohexenyl, fused cyclopentyl, or fused 2,3-furyl;

wherein R_4 is H, 1-hydroxyethyl, trifluoromethyl ether, or wherein R_3 and R_4 and the carbons to which they are attached form fused 5,6-cyclohexenyl, fused cyclopentyl or fused 2,3-furyl.


91. The compound of claim 86 having the structure:




wherein R₃ is straight chained C₃, C₄, C₆ or C₇ alkyl or branched C₅-C₇ alkyl or aryl.

92. The compound of claim 91, wherein R₃ is butyl, hexyl, heptyl, or benzyl.

93. The compound of claim 86, having the structure:




94. The compound of claim 86, having the structure:




180


95. The compound of claim 86, having the structure:



96. The compound of claim 86, having the structure:




97. The compound of claim 86, having the structure:




181


98. The compound of claim 86, having the structure:



99. The compound of claim 86, having the structure:




100. The compound of claim 86, having the structure:




182


101. The compound of claim 86, having the structure:



102. The compound of claim 86, having the structure:




103. The compound of claim 86, having the structure:




183


104. The compound of claim 86, having the structure:



105. The compound of claim 86, having the structure:




106. The compound of claim 86, having the structure:




184


107. The compound of claim 86, having the structure:



108. The compound of claim 86, having the structure:




109. The compound of claim 86, having the structure:




185


110. The compound of claim 86, having the structure:



111. The compound of claim 86, having the structure:




112. The compound of claim 86, having the structure:




186


113. The compound of claim 86, having the structure:



114. The compound of claim 86, having the structure:




115. The compound of claim 86, having the structure:




187


116. The compound of claim 86, having the structure:



117. The compound of claim 86, having the structure:




118. The compound of claim 86, having the structure:




188


119. The compound of claim 86, having the structure:



120. The compound of claim 86, having the structure:




121. The compound of claim 86, having the structure:




189


122. The compound of claim 86, having the structure:



123. The compound of claim 86, having the structure:




124. The compound of claim 86, having the structure:




190


125. The compound of claim 91, having the structure:



126. The compound of claim 91, having the structure:




127. The compound of claim 91, having the structure:




191


128. The compound of claim 91, having the structure:



129. The compound of claim 79, having the structure:




130. The compound of claim 79, having the structure:




192


131. The compound of claim 79, having the structure:



132. The compound of claim 79, having the structure:




133. The compound of claim 79, having the structure:




193


134. The compound of claim 79, having the structure:



135. The compound of claim 79, having the structure:




136. The compound of claim 79, having the structure:




194


137. The compound of claim 79, having the structure:



138. The compound of claim 79, having the structure:




139. The compound of claim 79, having the structure:




195


140. The compound of claim 79, having the structure:



141. The compound of claim 79, having the structure:




142. The compound of claim 79, having the structure:




196

143. The compound of claim 79, having the structure:



144. A compound having the structure:



wherein X = CH, C(CH₃) or N;

wherein each of R₁, R₂, R₃, R₄ and R₅ is independently H, C₁-C₁₀ straight chained or branched alkyl, C₂-C₁₀ straight chained or branched alkenyl, C₂-C₁₀ straight chained or branched alkynyl, C₃-C₁₀ cycloalkyl, substituted or unsubstituted aryl, hydroxy, halogenated ether, nitro, amino, halogen, -CN, -C(=Z)R₆, -C(=Z)OR₆, -C(=Z)N(R₆)₂, -N(R₆)-C(=Z)R₆, -N(R₆)-C(=Z)N(R₆)₂, -OC(=Z)R₆, -C(=Z)OR₆, -OR₆ or -SR₆;

wherein Z is O or S; and

wherein R_6 is C_1 - C_{10} straight chained or branched alkyl, aryl, $(CH_2)_nQ$, C_2 - C_{10} alkenyl, C_3 - C_{10} cycloalkyl, C_5 - C_{10} cycloalkenyl,

wherein Q is OR_7 , SR_7 , $N(R_7)_2$ or aryl,

wherein R_7 is H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl,

wherein R_2 and R_3 and the carbons to which they are attached form a fused aryl, heteroaryl, C_5 - C_{10} cyclic alkyl or heterocyclic alkyl ring; or wherein R_3 and R_4 and the carbons to which they are attached form a fused aryl, heteroaryl, cyclic alkyl or heterocyclic alkyl ring;

and wherein each alkyl, alkenyl, alkynyl and alkoxy group is optionally substituted with a substituent independently selected from R_a , where R_a is

- 1) hydroxy,
- 2) C_1 - C_{10} alkoxy,
- 3) halogen,
- 4) nitro,
- 5) amino,
- 6) CF_3 , or
- 7) carboxy,

and each cycloalkyl group is optionally substituted with a substituent independently selected from R_b , where R_b is

- 1) a group selected from R_a ,
- 2) C_1 - C_7 alkyl,
- 3) C_2 - C_7 alkenyl,
- 4) C_2 - C_7 alkynyl or

5) cyclic C₁-C₁₀ alkyl,

and each aryl is optionally substituted with R₁, and

wherein each R₆ and R₇ is independently acetate, formate, phosphate ester, dimethylglycine ester, aminoalkylbenzyl ester, aminoalkyl ester and carboxyalkyl ester.

145. The compound of claim 144, wherein R₆ and R₇ is independently acetyl or acyl.

146. A pharmaceutical composition comprising the compound of any one of claims 78-143 and a pharmaceutically acceptable carrier.

147. The pharmaceutical composition of claim 146, wherein the carrier is phosphate buffered saline, physiological saline or water.

148. A method of preparing a pharmaceutical composition comprising mixing the compound of any one of claims 78-143 with a pharmaceutical acceptable carrier.

149. The method of claim 148, wherein the carrier is phosphate buffered saline, physiological saline or water.


150. A compound which is converted in vivo to the compound of any one of claims 78-143.

199

151. A compound which is a metabolite of the compound of any one of claims 78-143.

152. A salt of the compound of any one of claims 78-143.

FIGURE 1
Correlation Between Binding Affinities at Human and Rat
Recombinant Neuropeptide FF Receptors



2/3

FIGURE 2





FIGURE 3



INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/30259

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 31/517, 31/47; A61P 13/10; C07D 239/72, 215/38.

US CL : 514/266.4, 313; 544/292; 546/159.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/266.4, 313; 544/292; 546/159.

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
CAS ONLINE; EAST

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X — A	US 4,563,460 B2 (KUHLA et. al.) 07 January 1986 (07.01.1986), column 3, lines 1-9.	144 1-143, 145-152
X — A	GB 1024907 B (BROWN) 06 April 1966 (06.04.1966), page 2, compounds on lines 45, 49, and 50.	144 1-143, 145-152
A	ROSOWSKY, A. et. al. Chemical and Biological Studies on Dihydro-s-triazines. XVI. Nmr Evidence for the Formation of 2-Guanidino-4-methylquinazolines as Anomalous Byproducts in the Three-Component Synthesis (1a, b). J. HET. CHEM. June 1972, Vol. 9, No. 3, entire document.	1-152
A	HUGHES, J. L. et. al. Cardiovascular Activity of Aromatic Guanidine Compounds. J. MED. CHEM. November 1975, Vol. 18, No. 11, especially page 1080.	1-152



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier application or patent published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

&

document member of the same patent family

Date of the actual completion of the international search

26 November 2002 (26.11.2002)

Date of mailing of the international search report

15 JAN 2003

Name and mailing address of the ISA/US

Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703)305-3230

Authorized officer

Mukund Shah

Telephone No. 703-308-1235

Mukund Shah

THIS PAGE BLANK (USPTO)